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1 INTRODUCTION 
1.1 Sex-determining region Y-box containing gene 9 (SOX9) 
SOX9 was first identified as a critical gene associated with Campomelic dysplasia 
(CD), a human haploinsufficiency disorder characterized by skeletal malformations, 
male-to-female sex reversal in XY males and neonatal lethality [1]. SOX9 belongs to 
SOX transcription factor family and possesses a high-mobility-group (HMG) DNA 
binding domain which exhibits a high degree of homology with that of the mammalian 
testis-determining factor, SRY [2]. 
1.2 General functions of SOX9 in physiological and disease states 
During embryonic development, SOX9 is widely expressed in chondrocytes, testes, 
heart, lung, pancreas, bile duct, hair follicles, retina, and the central nervous system 
(CNS) [3-8]. The functions of SOX9 involve the regulation of cell proliferation, 
differentiation, extracellular matrix (ECM) deposition, and epithelial-to-mesenchymal 
transition (EMT) [8, 9].  
In adult, SOX9 is expressed in local stem/progenitor cells of various organs with high 
turnover in physiological state [10-13].  SOX9 positive cells have the capability of 
differentiation into multiple mature organ cells, either in the physiological state or the 
regenerative state after injury, particularly in intestine, pancreas and hair follicles [10, 
11]. In some setting, SOX9 is required for the maintenance of progenitor cells in 
undifferentiated status [9, 14]. 
In fibrosis-associated disease, SOX9 regulates ECM deposition by activating genes 
encoding extracellular matrix components [15-19]. In addition, elevated SOX9 
expression has been reported in a wide range of human cancers, including non-small 
cell lung cancer (NSCLS), pancreatic ductal adenocarcinoma (PDAC) and melanoma 
[20-25]. The role of SOX9 in carcinogenesis is unclear. High levels of SOX9 
expression in cancers are linked to the malignant characters, progression, and poor 
prognosis of cancer. SOX9 exhibits pro-oncogenic properties, including promoting 
cell proliferation, inhibiting senescence and collaboration with other oncogenes in 
neoplastic transformation [26]. On the other hand, SOX9 displays as a tumor 
suppressor by inhibiting tumor cell growth and facilitating chemotherapy [26].  
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1.3 SOX9 in the liver  
1.3.1 Expression of SOX9 in embryonic and adult liver 
Most knowledge on the biological functions of SOX9 in liver development is obtained 
from studying animal embryonic development. In mice, SOX9 is the most specific and 
earliest marker of biliary tree during liver development [27]. At E10.5, SOX9 
expression is detected in the endodermal cells lining the liver diverticulum; however it 
is undetectable in the hepatoblasts invading the septum transversum [27]. At E11.5, 
SOX9 emerges in hepatoblasts near the portal vein [27]. At E13.5, the SOX9 positive 
cells form a single-layered ductal plate around the portal vein, which gives rise to 
cholangiocytes, the ductules, and the canals of Herings and periportal hepatocytes 
[27, 28]. At E15.5, SOX9 is expressed on the portal side of primitive ductal structure 
(PDC). From E18.5, SOX9 localizes in all biliary cells until birth [27]. After birth, SOX9 
expression persists in small bile ducts but regresses from large bile ducts [27].  
In human, SOX9 exhibits a similar expression pattern as in mice. During normal 
human liver embryonic development, SOX9 positive cells are detected near portal 
vein at 8 weeks post-conception (WPC). At 18 WPC, SOX9 expression is detected in 
the ductal plate encircling the portal vein. In adult, SOX9 expresses in bile ducts but 
not in hepatocytes [29]. SOX9 expression in embryonic and adult liver in mouse and 
human is presented in Table 1.  
1.3.2 Function of SOX9 in liver development 
SOX9 plays a critical role in controlling the timing of intrahepatic bile duct 
morphogenesis in liver development. Liver-specific inactivation of SOX9 leads to a 
delay in the resolution of the asymmetric primary ductal structures in mice [27]. In 
addition, SOX9 functions in cooperation with SOX4, another member of SOX family, 
in the process of bile duct development [30]. During mice bile duct development, 
SOX4 displays similar expression profiles in the PDC and developing bile duct as 
SOX9. Liver-specific inactivation of SOX4 leads to delayed bile differentiation and 
morphogenesis, while double mutation in SOX9 and SOX4 completely blocks biliary 
development and results in dilated and truncated hilar ducts, cholestasis, liver fibrosis 
and ductular reactions (DRs) [30]. In normal human fetal livers, accumulating studies 
have demonstrated that SOX9 expression is detectable in PDS with asymmetrical 
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expression, suggesting a similar bile duct morphogenesis process as in mice [27, 31, 
32]. 
Table 1. SOX9 expression in embryonic and adult liver  
Mouse Human 
Embryonic day SOX9 expression 
weeks 
postconception 
(WPC) 
SOX9 expression 
E10.5 Endodermal cells lining 
the liver diverticulum, 
undetectable in 
hepatoblasts 
  
E11.5 Hepatoblasts near 
portal vein 
8 WPC Hepatoblasts near 
portal vein 
E13.5 Single-layered ductal 
plate around the portal 
vein 
18 WPC Ductal plate 
encircling the portal 
vein 
E15.5 Portal side of primitive 
ductal structure (PDC) 
 
 
E18.5 to birth Biliary cells    
After birth Small ducts Adult Bile ducts  
 
1.3.3 SOX9 in liver homeostasis and regeneration 
In normal adult liver, SOX9 expression is observed in the periportal small intrahepatic 
ducts and peribiliary glands lining the large bile ducts [33]. In acute or chronic liver 
disease, SOX9 expression is detected in DRs which contain putative progenitors 
capable of producing cholangiocytes and hepatocytes[34]. Increasing evidence 
shows that a subpopulation of SOX9 positive cells in liver express stem cell markers, 
such as Epithelial cell adhesion molecule (EpCAM), neural cell adhesion molecule 
(NCAM), CD133, C-X-C chemokine receptor type 4 (CXCR4) [33, 35]. Thus, these 
SOX9 positive cells are thought as hepatic progenitor cells (HPCs) and are able to 
differentiate into hepatocytes and cholangiocytes. This notion is supported by several 
experimental evidences. Cardinale et al. showed that SOX9 positive cells isolated 
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from the peribiliary glands of adult human extrahepatic biliary system give rise to 
functional hepatocytes and cholangiocytes in vitro and in immunocompromised mice 
[35]. With the SOX9IRES-CreERT2 knock-in mice, Furuyama et al. illustrated that the 
adult HPCs locate in the SOX9-expressing progenitor cell zones and these SOX9 
positive cells physiologically supply the hepatocytes and intrahepatic biliary cells [11]. 
Dorrell C and colleagues conducted lineage tracing study using SOX9CreERT2 
transgenic mice and revealed that SOX9-expressing cells contribute to both 
hepatocytes and bile duct cell lineages in normal and injured livers [36]. However, the 
notion that SOX9 positive HPCs contribute to hepatocytes is not supported by other 
experiments. Tarlow et al. used the same strain of SOX9CreERT2 transgenic mice for 
lineage trancing as Dorrell’s. In contrast to Dorrell’s strategy, they adopted a lower 
dosage of tamoxifen to drive specific Cre expression. They found that hepatic 
progenitors of SOX9 positive ductal origin did not significantly contribute to 
hepatocyte replacement in different liver injury models [37]. The conflicting results 
from different studies may be attributed to two reasons. Firstly, in the SOX9IRES-
CreERT2 knockin mice, inserting IRES-CreERT2 into 3’UTR of the SOX9 gene may 
lead to endogenous SOX9 expression in the liver [11]. Secondly, although the 
SOX9CreERT2 transgenic mice maintain the intact genomic SOX9 locus, high dosage 
of tamoxifen may induce ectopic expression of SOX9 in the hepatocytes [28, 37]. In 
contrary to previous reported stem/progenitor-cell-based lineage tracing models, two 
groups performed hepatocyte-specific lineage tracing studies using adeno-
associated virus (AAV) to drive hepatocyte-specific Cre expression instead of 
tamoxifen. The results showed that liver homeostasis and regeneration are mediated 
by self-duplication of preexisting hepatocytes, rather than differentiation from HPCs in 
classic toxin-induced liver injury models [38, 39]. However, Lu and colleagues 
demonstrated that SOX9 positive HPCs contribute to liver regeneration when 
hepatocytes proliferation is impaired [40]. These results indicate that SOX9 positive 
HPCs may provide a backup system for injury states in which the proliferative 
capabilities of hepatocytes are impaired [39, 40]. 
1.3.4 SOX9 in chronic liver disease 
In chronic liver disease, hepatic stellate cells (HSCs) are primary cell type 
responsible for extracellular matrix (ECM) deposition  [41]. In response to liver injury, 
HSCs are activated by transforming growth factor β1 (TGFβ1) and platelet-derived 
growth factor (PDGF). Subsequently, activated HSCs secrete ECM that defines 
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fibrosis in the liver parenchyma [41]. Hanley et al. reported that activating HSCs 
under influence of TGF-β1 produce ectopic expression of SOX9, which leads to 
significant production of type I collagen [42]. In addition, SOX9 is responsible for the 
expression of Osteopotin (OPN), which is an important component of ECM and has 
been described as a biomarker for liver fibrosis [18]. As in the developmental and 
adult liver, SOX9 and OPN were coexpressed in biliary ducts. Increased expressions 
of both SOX9 and OPN colocalize to fibrotic region, particularly in activated HSCs. In 
vitro, SOX9 and OPN are coexpressed in activated human and rat HSCs, while 
abrogation of SOX9 expression results in decreased OPN expression [18]. Moreover, 
it has been reported that SOX9 is a downstream target of Hedgehog (Hh) signaling, 
which plays a crucial role in promoting EMT and the evolution of biliary fibrosis during 
chronic cholestasis [43].  
1.3.5 SOX9 in liver cancer 
Elevated SOX9 expression is detected in hepatocellular carcinoma (HCC) and 
cholangiocarcinoma (CCA) [44, 45]. In HCC, SOX9 expression is increased in tumor 
tissue and is positively related to tumor cell differentiation, venous invasion, 
advanced tumor stage and shorter overall survival [44, 46]. Functionally, SOX9 
confers stemness properties to HCC cells through Frizzled-7 mediated Wnt/β-catenin 
pathway [46]. In addition, Liu et al. reported that SOX9 is highly expressed in liver 
cancer stem cells (CSC) and required for maintaining the proliferation, self-renewal, 
and tumorigenicity of the liver CSCs [47]. SOX9 acts as a downstream regulator of 
Notch signaling through inhibition of Numb, an antagonist of Notch, thereby directing 
symmetrical cell division (SCD) and promoting tumorigenicity in liver CSCs [47]. In 
CCA, Matsushima et al. found that SOX9 expression decreases from the normal 
biliary epithelium to the biliary intraepithelial neoplasia in a stepwise pattern: SOX9 
expression in intrahepatic cholangiocarcinoma (iCCA) is lower than that in normal 
biliary epithelium [45]. However, elevated SOX9 expression in iCCA is associated 
with the biliary infiltration and poor clinical outcome [45]. Their results implied that 
SOX9 may be involved in a multi-step carcinogenesis of iCCA. 
1.4 Cholangiocarcinoma 
CCA is a heterogeneous carcinoma originating from bile duct system with 
cholangiocyte differentiation features [48]. 
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1.4.1 Epidemiology 
CCA is the second most common primary epithelial malignancy of liver following 
hepatocellular carcinoma [49]. CCA accounts for approximately 3% of all 
gastrointestinal cancers and 10% to 25% of primary hepatobiliary malignancies [50]. 
Advanced CCA has poor prognosis with a median survival of less than 24 months 
[51]. The incidence and mortality of CCA is increasing worldwide [52]. Figure 1 
presents the worldwide incidence of CCA from 1971 to 2009. Notably, the worldwide 
incidence of CCA varies greatly due to variations in geographic region and risk 
factors.  
 
Figure 1. Worldwide incidence of cholangiocarcinoma [52]. Data were collect from 1971 to 
2009.  Diagnoses of cholangiocarcinoma were made according to international classification 
of disease (ICD) codes. The trends of incidence were indicated as ↑, increasing; ↔, stable; 
or ↓, decreasing. The incidences for extrahepatic (eCCA or EH) and intrahepatic (iCCA or IH) 
cholangiocarcinoma were counted and the more incident type was indicated. 
1.4.2 Classification 
Anatomically, CCA is classified into intrahepatic (iCCA or ICC) and extrahepatic 
cholangiocarcinoma (eCCA) depending on the location of the tumor [53]. In detail, 
iCCA is defined as a cholangiocarcinoma locating proximally to the second degree 
bile ducts while eCCA confines to the area between the second degree bile ducts 
and ampulla of Vater. Moreover, the eCCA can be further divided into perihilar 
chonglangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA) with the 
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insertion of cystic duct as the separation point. pCCA localizes to the insertion of the 
cystic duct into the common bile duct, whereas dCCA confines to the area between 
the origin of the cystic duct and ampulla of Vater.  
Based on histological diversity, iCCA is categorized into two groups: pure muc-ICC 
and mixed-ICC (mucin-producing adenocarcinoma with hepatocytic differentiation 
areas and/or ductular areas) [54]. Muc-ICCs have similar clinicopathological, 
immunohistochemical, and gene expression profiles as hilar CCA. These tumors 
have a similar profile as cylindrical, taller, mucin-producing cholangiocytes that line 
hilar and intrahepatic large bile ducts [54]. However, mixed-ICC show similar 
clinicopathological, immunohistochemical, and gene expression profiles as 
cholangiolocellular carcinomas (CLCs) that comprise histopathological features of 
both hepatocellular carcinoma and cholangiocarcinoma and thus, are thought to 
originate from HPCs [54]. The proposed histological classification of CCA provides a 
new sight for understanding the biological features of CCA and may serve as a more 
accurate, reliable and simple approach for the diagnosis and treatment of the cancer. 
1.4.3 Risk factors 
Risk factors that lead to the multistep development of CCA are not well known. To 
date, most CCA cases lack a recognized risk factor. Moreover, most cases appear to 
develop in what is believed to be otherwise healthy livers. Approximately only 10% of 
cases resulted from a chronic inflammatory process of the bile ducts that might 
induce progressive changes in the biliary epithelium that culminate in cancer. 
Nevertheless, several well-established risk factors associated with the development 
of CCA have been reported, including parasitic infections, primary sclerosing 
cholangitis (PSC), biliary-duct cysts, hepatolithiasis, and thorotrast [55]. In addition, 
there are less-established or potential risk factors for CCA, including hepatitis C virus 
(HCV), hepatitis B virus (HBV), inflammatory bowel disease (IBD), cirrhosis, diabetes, 
obesity, alcohol, smoking, and host genetic polymorphisms [55]. Table 2 and 3 
present these recognized and potential risk factors of CCA.  
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Table 2. Established risk factors and corresponding geographic distribution for 
cholangiocarcinoma [55] 
Established risk factors Geographic distribution 
Hepatobiliary flukes  
Opisthorchis viverrini (O. viverrini) 
and Clonorchis sinensis (C. sinensis) 
 
Southeast and Northeast Asia 
Biliary-Tract Disorders: 
Bile-duct cysts 
 
Primary Sclerosing Cholangitis (PSC) 
 
 
Hepatolithiasis 
 
 
Prevalence is higher in Asian than Western 
countries 
Most common known risk factor of CCA in 
Western countries 
 
Established risk factor for ICC in Asian 
countries 
Toxins: 
Thorotrast 
 
 
Eastern and Western countries  
Table 3. Possible risk factors for cholangiocarcinoma [55] 
Possible Risk Factors 
Inflammatory Bowel Disease (IBD) 
Choledocholithiasis and Cholangitis 
Chronic Viral Hepatitis and Cirrhosis:  
                               Hepatitis C virus (HCV) 
                               Hepatitis B virus (HBV) 
                               Cirrhosis regardless of etiology 
Diabetes and Obesity 
Alcohol Drinking 
Smoking 
Genetic Polymorphisms 
1.4.4 Cellular origins 
For decades, the cell origin of CCA has been the object of extensive investigation. 
There is no doubt that mature cholangiocytes have the requisite to be targets of 
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transformation because of their self-renewal and longevity, which would allow the 
sequential accumulation of genetic or epigenetic mutations required for oncogenesis 
[56, 57]. However, several histopathologic and gene expression profiling studies 
have documented a group of CCA with the histopathological features of both 
hepatocellular carcinoma and cholangiocarcinoma, indicating a cell origin of CCA 
from HPCs localized in the canal of Hering [58-61].  Moreover, it has been proposed 
that the mucin-CCAs are derived from the PBGs, which are stem cell niches of the 
intrahepatic and extrahepatic biliary tree [62-64]. Thus, the cells lining the bile ducts, 
biliary epithelial cells (BECs), PBGs and HPCs can give rises to CCA. In addition, 
experimental studies even demonstrate that differentiated/mature hepatocytes can 
convert into biliary lineage cells through the activation of Notch signaling and have 
the potential to give rise to iCCA [65, 66].  Figure 2 shows the potential cells source 
of iCCA. 
 
Figure 2. Potential cells of origin in intrahepatic cholangiocarcinoma (iCCA) [53]. 
1.4.5 Molecular pathogenesis 
CCA is a cancer with genomic heterogeneity, which is not only related to the diverse 
anatomical location of the tumor but also to various risk factors and associated 
pathologies [52]. To date, the most prevalent genetic alterations identified in CCA 
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include DNA repair, the WNT-CTNNB1 pathway, tyrosine kinase signaling, protein 
tyrosine phosphatase, epigenetic and chromatin remodeling factors and deregulated 
Notch signaling, a critical component in cholangiocyte differentiation and biliary duct 
development [52]. 
In the epigenetic landscape, isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are 
frequently mutated in CCA [67, 68]. Mutation in IDH1 reshapes the genomic 
landscape and results in an altered differentiation state of cells [69]. In addition, IDH1 
mutation causes the deregulation of hepatocyte nuclear factor 4α (HNF4α), 
consequently blocks hepatocyte differentiation and promotes the development of bile 
duct cancer [70]. 
Fibroblast growth factor receptor 2 (FGFR2) gene fusions with multiple partners have 
been described in patients with CCA [71-75]. To date, seven FGFR2 fusion gene 
products have been identified in CCA, including FGFR2-BICC1, FGFR2-KIAA1589, 
FGFR2-TACC3, FGFR2–AHCYL1, FGFR2–MGEA5, FGFR2–KCTD1 and FGFR2–
TXLNA29 [52]. FGFR gene fusions facilitate oligomerization and FGFR kinase 
activation, which results in cell morphology alteration and increased cell proliferation 
[52, 74]. 
Several growth factor tyrosine kinases are involved in the carcinogenesis and 
progression of CCAs, including the ERBB family of receptor tyrosine kinases, such as 
the epidermal growth factor (EGF) receptor EGFR, and the hepatocyte growth factor 
(HGF) receptor HGFR, also known as c-Met. Immunohistochemistry studies showed 
EGFR overexpression in human CCA samples [76, 77]. Moreover, mutations and 
amplifications in the EGFR gene occur in 15% and 5% CCAs, respectively [78, 79]. In 
addition to EGFR, overexpression of c-Met is also associated with poor prognosis of 
CCA patients [80]. Both EGF/EGFR and HGF/c-Met pathways are implicated in the 
metastatic potential of CCA. Immunohistochemistry staining showed that cytoplasmic 
localization of E-cadherin is associated with EGFR overexpression. In vitro study 
further confirmed that EGF/EGFR axis triggers EMT of CCA cells [81]. Besides, 
stimulation of c-Met by HGF induces invasiveness and motility of CCA cells through 
activating AKT and ERK pathways [82]. These findings demonstrate the critical role 
of growth factors pathway in the progression of CCA. 
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CCA often arises in the context of biliary inflammation [50]. Whole-transcriptome 
analyses reveal two subclasses of iCCA with distinct molecular signatures: (1) iCCA 
with predominant activation of inflammatory pathways and overexpression of different 
cytokines, (2) iCCA of a proliferation class with feature of predominant activation of 
oncogenes [83]. One of the key cytokines, which is constitutively secreted by CCA 
cells, is IL-6 [84]. In vivo, elevated IL-6 expression is detected in the serum and tumor 
stroma of CCA patients [85, 86]. In vitro, IL-6 promotes cholangiocyte growth via the 
activation of the MAPK pathway and modulates the survival of CCA cells through the 
induction of anti-apoptotic proteins such as myeloid leukemia cell differentiation 
protein Mcl-1 (MCL1) [87]. In addition to IL-6, CCA cells also overexpress TGF-β and 
TGF-β receptor II [88, 89]. TGF-β contributes to the invasion and migration of CCA 
via induction of EMT of CCA cells [90]. The continuous production of inflammatory 
cytokines might induce the expression of inducible nitric oxide synthase (iNOS) and 
oxidative and nitrosative stress in cholangiocytes[91]. Oxidative and nitrosative stress 
further induce DNA damage by producing oxidative DNA lesions and inhibit DNA 
repair enzymes, thereby promoting carcinogenesis (Figure 3) [91, 92]. 
Notch, Wnt/ β-catenin, and Hh signaling pathways are involved in iCCA pathogenesis. 
Notch signaling pathway is required for modulating cell fate decisions throughout the 
development of invertebrate and vertebrate species [93]. In mammals, the canonical 
Notch signaling pathway has four Notch receptors (Notch 1, 2, 3 and 4) and five 
ligands belonging to the Jagged (Jagged1, 2) and Delta-like (Delta-like, Dll1, 3, and 4) 
family [94]. During liver embryonic development, the Notch signaling is critical for 
cholangiocyte differentiation and biliary duct morphogenesis [95]. In post-natal liver 
homeostasis and liver disease, Notch pathway is implicated in HPCs mediated liver 
repair and in reparative morphogenesis of the biliary tree [96]. In liver cancer, 
upregulated expression of Notch1 and Notch2 are reported in 82.2% and 56.1% of 
human CCAs, respectively [97]. In mice, the combined activation of Notch and AKT 
leads to hepatocytes-derived iCCA [65, 66]. Inhibition of Notch and its ligand Jagged 
1 almost eliminate mouse CCA development driven by transfection of activated AKT 
and Ras oncogenes [98]. In vitro, activation of Notch signaling is implicated in the 
induction of EMT and the migration of CCA cells [99]. Like Notch, the Wnt/β-catenin 
signaling pathway is upregulated in patients with cholangiocarcinoma [100]. The 
activation of Wnt pathway is often associated with overexpression of the ligands 
WNT7B and WNT10A along with several Wnt pathway target genes in human CCAs 
INTRODUCTION 
15 
[100]. An animal experiment that recapitulates the multi-stage progression of human 
CCA showed upregulated WNT7B and WNT10A during the course of CCA 
development [100]. The results indicated that the activation of canonical Wnt pathway 
may contribute to cholangiocarcinogenesis. In addition to Notch and Wnt signalings, 
the Hh ligand Sonic hedgehog protein is also overexpressed in human CCAs. In vitro, 
inhibition of its receptor Smoothened by cyclopamine inhibits proliferation and 
invasion of CCA cells [101]. Moreover, activation of Hh pathway by myofibroblast-
derived PDGF-BB protected CCA cells from TRAIL-induced apoptosis, indicating a 
preventive role of Hh signaling pathway in CCA [102].  
 
Figure 3. Summary of key molecular alterations involved in iCCA carcinogenesis [103]. 
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Table 4. Molecular pathogenesis of CCA [52]  
Gene or molecule Type of alteration 
Genetic and epigenetic factors  
TP53 
KRAS 
 
IL-6/STAT3, SOCS-3 
 
IDH1/IDH2 
Loss-of-function mutations 
Activating mutations in hotspots located at codon 
12 
Overexpression of IL-6 due to epigenetic 
silencing of SOCS-3 in 27 % of CCA  
Activating mutation in 10–23% of CCA 
Deregulated cell signaling pathways 
EGFR and ERBB2 
 
HGF/MET 
 
VEGF 
KRAS/MAPK  
Interleukin-6 (IL-6)/STAT 
Notch 
WNT/beta-Catenin 
Hedgehog 
Overexpression of the receptors occurs in 10–
32 % of iCCA 
Overexpression of MET occurs in 12–58 % of 
iCCA 
Overexpression in 50 % of iCCA 
Activation 
Overexpression and activation 
Upregulation of NOTCH1 and NOTCH2 
Upregulated  
Activation 
1.4.6 Treatment 
CCA is a devastating malignancy with limited treatment options. At present, surgical 
resection and liver transplantation represent the potentially curative treatment 
modalities for the all three types of CCA (intrahepatic, perihilar, and distal 
cholangiocarcnoma) [104]. However, the median survivals for R0-resected 
intrahepatic, perihilar, and distal CCAs were 80, 30, and 25 months, respectively, 
while the 5-year survivals were 63%, 30%, and 27%, respectively [105]. Moreover, 
curative liver transplantation is an option for selected patients with perihilar 
cholangiocarcinoma, while iCCA is considered as a contraindication for liver 
transplantation [53, 104]. For patients who are not suitable for surgical resection or 
liver transplantation, the prognosis is even more dismal with a life expectancy around 
1 year [106]. Currently, the practice standard for advanced CCA is systemic 
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chemotherapy with gemcitabine and cisplatin, which demonstrated a median overall 
survival around 11.7 months [107]. No molecular targeted therapy so far has been 
proven effective for CCA [104]. During the last decade, the application of next-
generation sequencing and other new technologies has made it feasible to discovery 
more potential targetable molecular alterations in CCA. Currently, clinical trials with 
targetable molecular alterations in CCA are undergoing.  BGJ398, a selective FGFR 
inhibitor, has shown efficacy in blocking the neoplastic transformation and growth of 
cell lines expressing FGFR2 fusion in vitro [108]. At present, clinical efficacy of 
BGJ398 is being investigated in a phase II multicenter single-arm study in advance 
CCA patient with FGFR2 alterations (ClinicalTrials.gov number. NCT02150967). 
Promising preliminary data have also been reported that treatment with ponatinib, a 
multikinase inhibitor, leads to reduction of tumor size in 2 iCCA patients of FGFR2–
TACC3 and FGFR2–MGEA5 gene fusions [71]. Furthermore, AG-120 and AG-221, 
inhibitor of IDH1 and IDH2, are currently being investigated in phase I 
(ClinicalTrials.gov number.NCT02073994) and phase I/II (ClinicalTrials.gov 
number.NCT02273739) clinical trials, respectively [109]. Since that the current 
existing stratification system based on the location and extent of the tumor in the 
biliary tree is not predictive for resect ability or survival of CCA patients [110], 
establishing a novel patient stratification system based on molecular biomarkers is 
essential for the development of more personalized therapeutic approaches for the 
treatment of CCA patients [109]. 
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1.5 Aims of this study 
On the basis of the aforementioned state of art, I learned that SOX9 is a critical 
transcription factor for liver embryogenesis, homeostasis, regeneration and HCC 
development. However, the oncogenic role of SOX9 has not been investigated in 
CCA. As CCA is a devastating malignancy with limited treatment options, elucidation 
of its underlying mechanisms and identification of new molecular markers for the 
tumorigenesis and progression of CCA is necessary for improving diagnosis and 
prognosis of this cancer type. Considering that (1) SOX9 positive HPCs are required 
for liver homeostasis and regeneration, (2) chronic injury increases the risk of forming 
liver cancer, (3) HPCs are a potential cellular origin of CCA, I hypothesized that 
SOX9 might contribute to the tumorigenesis of CCA. Thus, the aims of this study are 
(i) to investigate the oncogenic role of SOX9 in cholangiocarcinoma and (ii) to 
evaluate the therapeutic potential of targeting SOX9 as a treatment of CCA. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Patients and liver tissues 
Resected liver tissues were obtained from two cohorts: one cohort from Germany 
contains 28 iCCA patients and 5 eCCA; and the other cohort from France contains 41 
iCCA patients. In addition, 21 liver tissues from patients without liver cancer were 
enrolled as control. Basic characteristics of the enrolled iCCA patients are shown in 
Table 5. The study protocol fulfilled national laws and regulations and was approved 
by the local Ethics Committee. 
Table 5. Clinicopathological features of the validating set iCCA 
Clinicopathological 
Features 
NO. of patients Value 
Age (year mean±SD) 69 63.0±9.6 
Gender (male:female) 69 48:21 
Vascular invasion 10 (63) 15.9% 
Satellite nodules 20 (63) 31.7% 
Cirrhosis 22 (66) 33.3% 
AJCC classification 67  
I 23 34.33% 
II 18 26.87% 
III 10 14.93% 
IV 16 23.88% 
Follow up (month mean±SD) 60 28.4±26.6 
Range 60 0-110.5 
Death 30 50% 
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2.1.2 Chemicals and reagents 
Table 6. Chemicals and reagents 
Chemicals and reagents Cat. No. Company 
AC-DEVD-AFC (substrate) 13401 AAT Bioquest (USA) 
Acetic acid 338826 Sigma-Aldrich (USA) 
Albumin standard (BSA) 12659 Merck (Germany) 
Ammonium persulfate (APS) A3678 Sigma-Aldrich (USA) 
BIT 9500 09500 Stem cell (Canada) 
3.3'-diaminobenzidine (DAB) D-5905 Sigma-Aldrich (USA) 
DMEM BE12-709F Lonza (Germany) 
DMEM/F12 12634-010 Life Technology (Canada) 
Dimethyl sulfoxide (DMSO) 41639 Sigma-Aldrich (USA) 
DRQ5 dye 4084 Cell SignalingTechnology 
(USA) 
Peroxidase Blocking Reagent S2003 Dako (Danmark) 
Dulbecco’s Phosphate Buffered 
Saline 
D8537 Sigma Aldrich (Germany) 
EDTA 324503 Calbiochem (Germany) 
Epidermal growth factor (EGF) 354001 BD Biosciences (USA) 
Erlotinib 5083S Cell Signaling Technology 
(USA) 
Ethanol 100% K928.4 Carl Roth (Germany) 
Fetal Bovine Serum (FBS) 10270-098 Invitrogen (Germany) 
Formaldehyde F1635 Sigma-Aldrich (USA) 
L-glutamine BE17-605E Lonza (Germany) 
Hematoxylin HX69715174 Carl Roth (Germany) 
Hydrogen peroxide (H2O2) H1009 Sigma-Aldrich (USA) 
Laemmli-buffer 161-0737 BioRad (USA) 
Insulin HI0210 Lilly (Germany) 
Malinol mounting medium 3C-242 Waldeck (Germany) 
2-β-Mercaptoethanol 516732 Sigma-Aldrich (Germany) 
Mounting medium S3023 Dako 
Methanol 8388 Carl Roth (Germany) 
MTT reagent M5655 Sigma Aldrich (Germany) 
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Penicillin/streptomycin A2210 Biochrom KG 
Phosphatase Inhibitor Cocktail 2 P5726 Sigma-Aldrich (Germany) 
Protease Inhibitor Cocktail 
Tablets  
S8820 Sigma-Aldrich (Germany) 
Propidium Iodide (PI) P-1470 Sigma-Aldrich (Germany) 
RPMI1640 31870 Thermo Fisher Scientific 
(USA) 
RNase A 19101 Qiagen (Germany) 
Sodium dodecyl sulfate (SDS) L3771 Sigma-Aldrich (Germany) 
Supersignal Ultra      34095 Thermo Fisher Scientific 
(USA) 
TEMED T9821 Sigma-Aldrich (Germany) 
TGF-β1 100-21 Peprotech 
TRIS  4855 Carl Roth (Germany) 
Triton® X-100 T-9284 Sigma-Aldrich (Germany) 
Trypsin/EDTA 10x T4174 Sigma-Aldrich (Germany) 
Tween® 20 9127.2 Carl Roth (Germany) 
   
 
2.1.3 Antibodies 
Table 7. Primary antibodies used for immunoblotting 
Antibody Company Cat. No. 
Predict molecular 
weight 
SOX9 Sigma Aldrich HPA001758  70kDa 
Cytokeratin 19 Santa Cruz Biotechnology sc-6278 40kDa 
EpCAM Abcam ab32392 39kDa 
p21WAF1/Cip1 Sigma Aldrich P1484 21kDa 
p27 Kip1 Cell Signaling Technology #2552 27kDa 
p16 INK4A Cell Signaling Technology #4824 16kDa 
p53 Cell Signaling Technology 9282S 53kDa 
pERK1/2 Santa Cruz Biotechnology sc-7383 42/44kDa 
ERK 1/2 Santa Cruz Biotechnology sc-135900 42/44kDa 
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MRP4 Abcam ab15598 230kDa 
pChk1(Ser345) Cell Signaling Technology 2341T 56kDa 
Chk1 Cell Signaling Technology #2360 56kDa 
pChk2(Thr68) Cell Signaling Technology #2661 62kDa 
pEGFR Cell Signaling Technology #2234 175kDa 
Bcl-xL Cell Signaling Technology 2764 30kDa 
Bcl-2 Cell Signaling Technology 2870 26kDa 
Cyclin D1 Cell Signaling Technology #2978 36kDa 
E-Cadherin Cell Signaling Technology 3195S 135kDa 
β-catenin Sigma C7207 92kDa 
Vimentin Abcam ab20346 54kDa 
N-cadherin Abcam ab12221 130kDa 
Alpha-Tubulin Abcam ab4074 55kDa 
GAPDH Santa Cruz Biotechnology sc25778 37kDa 
 
Table 8. Primary antibodies used for immunohistochemistry 
Antibody Species Company Cat. No. Dillution 
SOX9 rabbit Sigma Aldrich 
HPA001
758  
1:100 
Cytokeratin 19 mouse 
Santa Cruz 
Biotechnology 
sc-6278 1:100 
 
Table 9. Primary antibodies used for immunofluorescence 
Antibody Species Company Cat. No. Dillution 
β-catenin mouse Merck/Millipore 05-665 1:100 
E-Cadherin rabbit Cell Signaling Techonogy 3195s 1:100 
 
 
 
MATERIALS AND METHODS 
23 
Table 10. Secondary antibodies  
Antibody Source Dilution 
in WB 
Dilution 
in IHC 
Dilution 
in IF 
Goat anti rabbit IgG HRP Santa Cruz 1:10000 ------ ------ 
Goat anti mouse IgG HRP Santa Cruz 1:10000 ------ ------ 
Goat anti rabbit IgG HRP DAKO ------ 1:200 ------ 
Goat anti mouse IgG HRP DAKO ------ 1:200 ------ 
Goat-anti-rabbit  Rhodamine Merck/Millipore ------ ------ 1:200 
Goat-anti-mouse FITC Merck/Millipore ------ ------ 1:200 
 
2.1.4 Buffer preparation 
Table 11. Buffer  
Chemicals Ingredient 
APS (for WB) 1g APS 
add to 10ml ddH2O 
Ladder (for WB) 950 µl Laemmli buffer 
50 µl β-mercapto ethanol 
RIPA buffer, stock  50 mM Tris-HCl pH 7.2-7.6  
150 mM NaCl    
 2 mM EDTA    
 0.1 % SDS  
 0.5 % Sodium-Desoxycholate   
1% Nonidet P-40  
10% v/v Glycerol 
Lysis buffer, ready to use (for WB) 90  µl RIPA buffer 
1 µl Phosphatase Inhibitor 
15 µl Protease Inhibitor 
NL buffer 50mM Tris HCl pH 8.0 
150mM NaCl,  
1% NP-40 
0.5% sodium deoxycholate 
0.1% SDS  
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1% glycerol 
Lysis buffer (for caspase 3 activity) 50 mM HEPES 
100 mM NaCl 
0.1% CHAPS 
1 mM DTT 
0.1 mM EDTA pH 7.4 
Reaction Buffer 50 mM HEPES 
100 mM NaCl 
0.1% CHAPS 
10 mM DTT 
0.1 mM EDTA 
10% (w/v) glycerol  pH 7.4 
0.3% PBST 
 
1% BSA 
PBS, 1× 
0.3 % Tween20 
20mg BSA 
20ml 0.3% PBST 
TBS, 10×  24.23g 0.2M Tris PH7.5,  
58.44g 1M NaCl,  
add to 1L ddH2O  
adjust pH value to 8.0 
TG, 10x  30.27 g 0.2M Tris,  
144g Glycine,  
add to 1L ddH2O 
Adjust pH value to 8.3 
Transfer buffer 1× 
 
 
Running buffer 1x 
 
 
TBST 
100ml TG 10×, 
200ml methanol, 
add to 1L ddH2O 
100ml TG 10x 
10ml 10%SDS 
Add to 1L ddH2O 
100ml TBS 10x 
10ml 10%Tween 20 
Add to 1L ddH2O 
SF buffer 250mM Sucrose 
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20mM HEPES pH7.4 
1.5mM MgCl2 
10mM KCl 
1mM EDTA 
1mM EGTA 
 
2.1.5 Cell culture material 
Table 12. Cell culture materials 
Material Company 
Cell culture flasks 25 cm2 / 75 cm2 / 175 cm2 Greiner Bio-one(Germany) 
Cell scraper Falcon (Germany) 
Conical centrifuge tubes 15 ml / 50 ml Falcon (Germany) 
Cell culture plate 96 well (white) Greiner Bio-one (Germany) 
Cell culture plate 96 well (flat bottom)  Greiner Bio-one(Germany) 
Cell culture plate 24 well Greiner Bio-one(Germany) 
Cell culture plate 12 well Greiner Bio-one(Germany) 
Cell culture plate 12 well (non-adherent) Greiner Bio-one(Germany) 
Cell culture plate 6 well Greiner Bio-one(Germany) 
0.5 or 1.5 ml tube  Eppendorf, Germany 
Eppendorf epT.I.P.S  Eppendorf, Germany 
Inserts with 8 μM pore size Falcon (Germany) 
Microscope slide Carl Roth (Germany) 
PCR-Tubes™ 0.2 m Life Technology (Germany) 
Petri dishes  Falcon (Germany) 
Flow cytometry tubes  Falcon (Germany) 
Sterile pipette Greiner Bio-one(Germany) 
2.1.6 Instruments and Software 
Table 13. Instruments and Software 
Instruments or softwares Company 
BD FACS Canto II BD Becton Dickinson 
(Germany) 
Centrifugation  Eppendorf (Germany) 
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TCS SP2 Confocal microscope Leica (Germany) 
FlowJo software 10.1 Tree Star (USA) 
GraphPad Prism 5.0 GraphPad Software, Inc 
(USA) 
Immunofluoerscence optical microscopy Olympus (Germany) 
Incubator for Cell culture  Heraeus GmbH (Germany) 
Infinite M200 Tecan  
Inverted microscopy Zeiss (Germany) 
Image J National institute of Health  
Light microscope Leica (Germany) 
Microwave oven  Sharp (USA) 
pH-Meter 538 Multical WTW (Germany) 
Real-time PCR Biosystems 
Weight balance  Sartorius (Germany) 
Western-Blot imaging system Chemismart 5100 PEQLAB (Germany) 
2.2 Methods 
2.2.1 Immunohistochemical staining  
Protocol for immunohistochemistry 
Tissue type: formalin-fixed, paraffin-embedded specimens 
Note: Do not allow slides to dry at any time during this procedure.  
Day1 
Step1: Deparaffinization and rehydration 
 Incubate sections in 3 times xylene for 5 minutes each time (1)
 Incubate sections in 1 time washes of 100% ethanol for 10 minutes (2)
 Incubate sections in 1 time washes of 100% ethanol for 5 minutes (3)
 Incubate sections in 1 time washes of 96% ethanol for 5 minutes (4)
 Wash sections 2 times in PBS for 5 minutes each time (5)
Step2: Antigen Unmasking  
Heat-induced epitope retrieval using a microwave with 1mM EDTA (Disodium salt) 
solution, pH8.4 
Total 10 min:  10 to15 seconds boiling 
                       45 to 50 seconds waiting 
Cool slides on bench to room temperature. 
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Step3: Blocking 
 Wash sections in PBS 3x times for 10 minutes each time. (1)
 Blocking: incubate sections in DAKO Blocking Peroxide for 30 minutes. (2)
Alternatively, wash the sections for 1 time with PBS, and then incubate sections in 
0.3 %H2O2 for 15 minutes. 
Step4: Staining primary antibody 
 Wash sections in PBS twice for 10 minutes each. (1)
 Dilute the primary antibody to the indicated concentration (Table 8) and adds the (2)
diluted antibody to the sections. 
 Incubate sections overnight at 4°C.  (3)
Day 2 
Step5: Staining secondary antibody 
 Remove primary antibody and wash sections in PBS 3 times for 10 minutes each (1)
time.  
 Add corresponding secondary antibody diluted to the indicated concentration (2)
(Table 10) in PBS to each section and incubate for 45 minutes at room 
temperature. 
 Remove secondary antibody and rinse sections 3 times with PBS for 10min. (3)
Step6: Staining to detect horse radish peroxidase (HRP) 
 Prepare DAB solution: add 10mg DAB in 15ml 50mM Tris (hydroxymethyl)-(1)
aminomethean solution (pH 7.6), and then filter the clumps.   
 Add 12µl H2O2 to the DAB solution to active DAB, and then add the activated (2)
DAB to each section and monitor staining under a microscope.  
Note: Let the sections develop 10 minutes but do not exceed 10 minutes and 
immerse slides in ddH2O. 
 Counterstain sections in hematoxylin for 10 to 30 seconds. (3)
 Wash sections using tap water for 10 minutes. (4)
Step7: Dehydrate sections 
 Incubate sections in 95% ethanol 2 times for 10 seconds each time. (1)
 Repeat in 100% ethanol, incubating sections two times for 10 seconds each time. (2)
 Repeat in xylene, incubating sections two times for 10 seconds each time. (3)
 Mounted the sections with malinol mounting medium. (4)
Step8: Record the staining results using Leica upright research microscope 
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2.2.2 Immunohistochemistry evaluation 
Immunostaining results for SOX9 were scored semi-quantitatively based on the 
intensity score and proportion score of positively stained tumor cell nuclei. In detail, 
the intensity score of SOX9 nuclear staining was defined as four grades: 0, negative; 
1, weak with color yellow; 2, middle with color brown; 3, strong with color black. The 
number of SOX9 positive cell nuclei was defined as 6 grades: 0, no positive cells; 1, 
positive cells: ≤ 1%; 2, 1% < positive cells ≤ 10%; 3, 11% < positive cells ≤ 33%; 4, 
34% < positive cells ≤ 66%; 5, 66% < positive cells.  The final immune staining 
scores were calculated as number intensity by multiplying the intensity score and 
proportion score. The samples with final scores over 10 were identified as high SOX9 
expression, and the others were identified as low SOX9 expression. The 
representative pictures of SOX9 staining and for semi-quantitative scoring system are 
presented in Figure 4. CK19 expression was categorized into high expression and 
low expression according to the immunoreactivity (Figure5). 
 
Figure 4. A semi-quantitative scoring system for evaluation of SOX9 expression in 
intrahepatic cholangiocarcinoma. Representative images show the intensity and proportion 
scores of the positively stained tumor cell nuclei for the evaluation of SOX9 expression in 
iCCA. 
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Figure 5. CK19 expression in iCCA (Immunohistochemistry staining). 
2.2.3 Cell lines  
Cell lines used in this study are presented in Table 14.  
Table 14. Cell lines and cell culture medium used in the study 
Cell lines Culture medium reference 
iCCA  
CC-SW-1 DMEM, 10% FCS, 5ml P/S*, 10ml L-Glutamine [111] 
HuCCT-1 
RPMI 1640 Medium with 10% FBS, 5ml P/S, 10ml L-
Glutamine 
[112] 
HCCC-
9810 
RPMI 1640 Medium with 10% FBS, 5ml P/S, 10ml L-
Glutamine 
 
eCCA TFK-1 
RPMI 1640 Medium with 10% FBS, 5ml P/S, 10ml L-
Glutamine 
[113] 
EGI-1 DMEM, 10% FCS, 5ml P/S, 10ml L-Glutamine  
NBEC* MMNK-1 DMEM, 10% FCS, 5ml P/S, 10ml L-Glutamine [114] 
mHPCs* BMOL 
William E, 10%FCS, 5ml P/S, 10ml L-Glutamine, 30ng/ml 
IGF-2, 50ng/ml EGF, 10µg/ml 
[115] 
 
*: NBEC: normal biliary epithelial cells, mHPCs: mouse HPCs, P/S: penicillin/streptomycin 
2.2.4 Cell culture and treatment 
All the cell lines were cultured in a humidified incubator at 37° and 5% CO2 
atmosphere. For transient transfection of siRNA, cells were treated with indicated 
culture medium without penicillin/streptomycin. Cells underwent starvation without 
FBS medium for 10 to 16 hours before treating with 10ng/ml epidermal growth factor 
(EGF). EGFR inhibitor Erlotinib and ERK1/2 inhibitor U0126 were dissolved in DMSO 
to make a 10 mM stock solution and diluted with cell culture medium into indicated 
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concentration during treatment. 0.1% DMSO was diluted in the same manner as 
control. Gemcitabine was provided by Prof. Lu LG (Shanghai Jiao Tong University 
School of Medicine) was dissolved in phosphate-buffered saline to make a 100mM 
stock solution and diluted with cell culture medium into indicated concentration during 
treatment. 
2.2.5 RNA interference (RNAi) of SOX9 
Pooled small interfering RNA (siRNA) targeting human and mouse SOX9 were 
purchased from Dharmacon (human M-021507-00). 
Protocol for SOX9 siRNA transfection 
Day1: Seeding cells for transfection 
Tumor cells were plated at a density of 1.5 × 105 cells per well with 2ml 
corresponding growth medium in a six-well cell culture vessels. 
Day2:  
For SOX9 siRNA transfection 
Step1: Prepare RNA-lipid complexes 
 Dilute RNAiMAX reagent in Opti-MEM medium by adding 1.5 μl RNAiMAX into (1)
100 μl Opti-MEM medium in tube A. 
 Dilute siRNA in Opti-MEM medium by adding 20 pmol SOX9 siRNA into 100 μl (2)
Opti-MEM medium in tube B. 
 Add diluted siRNA to diluted RNAiMAX reagent with a ratio of 1 to 1. Then, (3)
incubate the mixture for 20 minutes at room temperature. 
Step2: Change the culture medium to 500 µl Opti-MEM medium per well. Then, add 
RNA-lipid complexes to cells. 6 hours later, change the Opti-MEM medium to 2 ml 
cell culture medium. RNA and whole cell protein were extracted 48 hours and 60 
hours after transfection for measuring knockdown and overexpression efficiency. 
2.2.6 Whole cell protein extraction 
Wash the cells twice with ice-cold PBS and immediately add 70 μl RIPA buffer to per 
well of 6-well plate and put on ice. Thereafter, scrape the cells to collect lysate and 
transfer to a 1.5 ml Eppendorf tube. Subsequently, centrifuge at 13000rpm at 4 °C for 
5 minutes. Collect the supernatant in a fresh 1.5 ml Eppendorf tube. 
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2.2.7 Cell Subcellular fractionation  
Cell subcellular fractionation was performed following the protocol by Huang et al 
[116]. The following is a modified protocol from Huang et al reported. 
Protocol of cell subcellular fraction 
Step1: Extraction of the whole cell protein 
Wash the cells twice with ice-cold PBS. Then, immediately add 150 μl SF buffer to 
per well of 6-well plate and put on ice. Thereafter, scrape the cells to collect lysate 
and transfer to a 1.5 ml Eppendorf tube. Agitate cell lysates at 4 °C for 30 minutes at 
50 rpm on a tube roller. Subsequently, centrifuge at 720 g at 4 °C for 5 minutes. 
Collect the supernatant in a fresh 1.5 ml Eppendorf tube for next step3. 
Step2: Extract the nuclear fraction 
Wash the pellet from step1 with 300μl of SF buffer and disperse the pellet with a 
pipette. Then, centrifuge the lysate at 720 g at 4°C for 10 minutes. Thereafter, re-
suspend the pellet in NL buffer and agitated at 4 °C for 30 minutes at 50 rpm on a 
tube roller. This is the nuclear fraction including nuclear membranes. 
Step3: Extract the cytosolic and membrane fraction  
Centrifuge the supernatant from step1 at 10.000 x g at 4°C for 10 minutes. Carefully 
transfer the supernatant to a new 1.5 ml Eppendorf tube. This is the cytosolic and 
membrane fraction. 
2.2.8 Protein concentration determination 
Protein concentrations were assessed with a Bio-Rad protein assay. After harvesting 
protein lysates, 20 µl Reagent S diluted with Reagent A (1:50) were added into a 96 
well plate followed by 2 µl of each sample and mixed with 200µl reagent B. The plate 
was incubated for 10 minutes at room temperature on the shaker. Then, the 
concentrations of samples were quantified by Infinite M200 at 595nm. A standard 
curve was produced by quantifying BSA samples of standard concentration (0.125, 
0.25, 0.5, 1, 1.5, 2 mg/ml). 
2.2.9 Immunoblotting 
20μg of total cell protein extracts were subjected to 10% or 12% sodium dodecyl 
sulfate polyacrylamide electrophoresis (SDS-PAGE) gel and transferred to 
nitrocellulose membranes. 5% BSA in Tris-buffered saline with Tween 20 (TBST) 
was used to block nonspecific binding. Membranes were probed with primary and 
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secondary antibodies in TBST according to manufacturer’s instructions. HRP-linked 
anti-mouse, anti-rat and anti-rabbit antibodies were used as secondary antibodies. 
Alpha-tubulin and GAPDH were used as loading control. Signal was visualized by 
incubating the blots in Supersignal Ultra (Pierce, Hamburg, Germany). 
2.2.10 MTT assay 
After knockdown of SOX9 expression, cells were treated with 0.25% trypsin to make 
single cell suspension and re-plated in a 96-well plate at a density of 2.0 × 103 cells 
per well with 100µl growth medium. 2 days after the cells attachment, cells were 
incubated with 5mg/ml MTT reagent for 5h. Then, the supernatant was removed 
carefully and 100µl solvent solution containing 40% of 10% SDS, 40% DMSO and 
20% Acetate acid solution (600µl Acetate acid/50mL PBS) was added and incubated 
overnight for measurement. Absorbance was measured at 570nm with a reference to 
630 nm. For proliferation assay, cells were incubated in 96-well plate for 48 hours 
before incubation with MTT. For gemcitabine IC50 measurement, cells were 
incubated for 6 h for attachment. Then, cells were treated with serial concentrations 
of gemcitabine for 48 hours before incubating with MTT. 
2.2.11 Cell cycle analysis 
Cells were harvested at 48 hours after siRNA treatment and washed with cold PBS, 
then fixed with 70% cold ethanol. The cells were re-suspended in solution containing 
TritonX-100 (0.1%) and 100µg/ml RNase to remove RNA. The samples were stained 
with propidium iodide (20μg/mL) for 30 minutes in the dark, and then subjected to 
analysis for DNA content using FACS Calibur (BD Biosciences, Heidelberg, 
Germany) and data analysis was performed using Flowjo version10 software. 
2.2.12 Transwell migration assay 
Cell culture inserts with 8μM pore size (Falcon) were used.  For tumor cell migration, 
2.0× 105  CCA tumor cells were suspended in RPMI 1640 or DMEM medium with 
0.5% FBS and plated in the upper chambers. The lower chambers were filled RPMI 
1640 or DMEM with 10% FBS. After 16 h, the medium in the inserts were removed 
and washed with PBS. The inserts were filled with 3.7% formaldehyde for 5 minutes. 
Subsequently, incubate the inserts in methanol for 30 minutes. The filters were 
stained with 10% Gimsa (Sigma, St. Louis, MO) for 15 minutes. The inner side was 
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wiped with cotton swaps. The migrated cells were count under an inversed 
microscope. 
2.2.13 Caspase 3 assay 
Caspase 3 assay was performed as previously described [117]. In detail, after wash 
the cells with ice-cold PBS, immediately add 70 µl Caspase 3 lysis buffer to per well 
of 6-well plate and put on ice. Lysates were collected by cell scraper and put into 
1.5ml tube followed by centrifugation at 13000rpm for 10min at 4°C. Supernatant in 
each tube was collected into a new 1.5ml tube and stored at -20°C until use. Then, 
20 µl cell extracts were added to 70µl Caspase 3 reaction buffer and 10 µl AC-
DEVD-AFC caspase 3 fluorimetric substrate (Biomol, Hamburg, Germany) in a white 
96-well plate. Then, the plate was incubated for 90 minutes at dark. Subsequently, 
Caspase 3 activity was detected by fluorometric measurement using Tecan infinite 
M200 (excitation 400 nm; emission 505 nm). Protein concentrations of the cell 
extracts were measured by Bio-Rad protein assay as mention in protein 
concentration determination. The caspase3 activity was normalized with the 
absorbance intensity dividing the protein concentration and expressed as relative 
fluorescent units (RFU) per minute per mg protein. 
2.2.14 Tumor sphere formation assay 
The protocol used for tumor sphere formation culture was as previously described 
with modification [118]. 12 hours after SOX9 knockdown, cells were washed with 
PBS and treated with 0.25% trypsin7 EDTA to make single cell suspension. Then, 
cells were suspended in serum-free DMEM/F12 containing 10% BIT 9500 and 2mM 
L-glutamine supplied with 10ng/ml human recombinant epidermal growth factor 
(EGF), 10ng/ml human recombinant basic fibroblast growth factor (FGF-2) and 1% 
penicillin-streptomycin. Thereafter, culture the cells in non-adherent 12-well plates at 
a density of 1 × 104/ml pre well. After 10 days incubation, tumorsphere numbers are 
counted under a Leica phase-contrast microscope using the 20x magnification lens. 
Tumor spheres bigger than 100 µm are considered as positive.  
2.2.15 RNA isolation and RNA concentration determination 
Total cell RNA was extracted using the InviTrap spin universal RNA mini kit (Stratec, 
Berlin, Germany), according to the manufacturer’s instruction. 
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Protocol for RNA isolation modified from the Instruction for the InviTrap® Spin 
Universal RNA Mini Kit 
Step1: Cell disruption 
Wash the cells twice with ice-cold PBS. Then, immediately add 300μl β-
mercaptoethanol-containing lysis solution TR to per well of 6-well plate. Thereafter, 
scrape the cells to collect lysate and transfer to a 1.5 ml Eppendorf tube and stored 
at -80°C until use. 
Step2: Binding of genomic DNA to the DNA-Binding Spin Filter 
Pipet the lysate resulting from step1 directly onto the DNA-Binding Spin Filter placed 
in a 2 ml Receiver Tube. Incubate the sample for 1 min and centrifuge at 13.000rpm 
for 2 minutes. Discard the DNA-Binding Spin Filter.  
Step3: Adjust RNA binding conditions 
Add 250μl 70 % ethanol to the RNA containing lysate and mix thoroughly by pipetting 
up and down. 
Step4: Binding of the total RNA to the RNA-RTA Spin Filter 
Pipet the sample from step 3 onto a RNA-RTA Spin Filter and incubate for 1 min and 
centrifuge at 13.000rpm for 1 minute. Discard the flow-through. 
Step5: 2 times wash of the RNA-RTA Spin Filter 
Add 600μl Wash Buffer R1 onto the RNA-RTA Spin Filter and centrifuge for 1 min at 
13.000rpm. Discard the flow-through. Then Add 700 μl Wash Buffer R2 onto the 
RNA-RTA Spin Filter and centrifuge for 1 min at 13.000rpm. Discard the flow-
through. Drying of the RNA-RTA Spin Filter membrane to eliminate any trace of 
ethanol by centrifuging for 4 min at maximum speed. 
Step6: Elution of total RNA 
Transfer the RNA-RTA Spin Filter into a RNase-free Elution Tube and pipet 40μl of 
Elution Buffer R directly onto the membrane of the RNA-RTA Spin Filter. Incubate for 
2 min and centrifuge for 1 min at 13.000rpm. Discard the RNA-RTA Spin Filter and 
place the eluted total RNA immediately on ice. 
Step7: RNA concentration determination 
RNA concentration was photometric determined by measuring the RNA solution in a 
nanocrystalline plate at 260nm with Tecan infinite M200.  
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2.2.16 Quantitative real-time reverse transcription polymerase chain reaction 
For first strand cDNA synthesis, reverse transcription of 500ng RNA was performed 
with random primer (Thermo Scientific) and RevertAid H Minus M-MuLV reverse 
transcriptase (Thermo Scientific) according to the manufacturer’s instructions and 
subsequently diluted with nuclease-free water (Invitrogen) to 10ng/µl cDNA. For PCR 
amplification, 10.4µl mixtures contained 5µl (50ng) template cDNA, 5µl SYBR Green 
(4367659, Life Technologies), and 4µM forward and reverse primer PCRs were run 
in triplicate and performed on a StepOnePlus Real-time PCR (Applied Biosystems). 
PCR amplification cycling conditions comprised 10 min polymerase activation at 95 
°C and 40 cycles at 95°C for 15s and 60°C for 1 min. A melting curve analysis was 
performed for each PCR analysis. Relative quantification of target genes was 
normalized against the house keeping gene PPIA. The reverse and forward primers 
used for the current study are listed in Table 15.  
Table 15. Primers used for qRT-PCR in this study 
Primer Forward Reverse 
SOX9 AGCGCCCCCACTTTTGCTCTTT CCGCGGCGAGCACTTAGGAAG 
EpCAM AATCGTCAATGCCAGTGTACTT TCTCATCGCAGTCAGGATCATAA 
ABCB1 AAATTGGCTTGACAAGTTGTATATGG CACCAGCATCATGAGAGGAAGTC 
ABCG2 TCATCAGCCTCGATATTCCATCT GGCCCGTGGAACATAAGTCTT 
ABCC6 TTGGATTCGCCCTCATAGTC GGTAGCTGGCAAGACAAAGC 
PPIA AGGGTTCCTGCTTTCACAGA CAGGACCCGTATGCTTTAGG 
2.2.17 Microarray analyses and Gene set enrichment analysis (GSEA) 
Total RNA from cell cultures were isolated as described in RNA isolation. Total RNA 
(10 μg) from samples was tested for quality using an Agilent 2100 Bioanalyzer Chip, 
reverse transcribed. Gene expression profiling was performed using arrays of human 
HuGene-2-0-st-type from Affymetrix. The following protocol was kindly provided by 
Dr. Carolina De La Torre in Zentrum für Medizinische Forschung of Medical Faculty 
of Mannheim of Heidelberg University. In detail, biotinylated antisense cDNA was 
then prepared according to the Affymetrix standard labelling protocol with the 
GeneChip® WT Plus Reagent Kit and the GeneChip® Hybridization, Wash and Stain 
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Kit (both from Affymetrix, Santa Clara, USA). Afterwards, the hybridization on the 
chip was performed on a GeneChip Hybridization oven 640, then dyed in the 
GeneChip Fluidics Station 450 and thereafter scanned with a GeneChip Scanner 
3000. All of the equipment used is from the Affymetrix-Company (Affymetrix, High 
Wycombe, UK). A Custom CDF Version 21 with ENTREZ based gene definitions was 
used to annotate the arrays. The Raw fluorescence intensity values were normalized 
applying quantile normalization and RMA background correction. OneWay-ANOVA 
was performed to identify differential expressed genes using a commercial software 
package SAS JMP10 Genomics, version 6, from SAS (SAS Institute, Cary, NC, 
USA). A false positive rate of a=0.05 with FDR correction was taken as the level of 
significance. 
Integrated analysis of gene expression signatures of CCA patients was performed on 
a dataset GSE26566 from Andersen JB et al [86], which is a publicly available gene 
expression dataset from Gene Expression Omnibus (GEO). GSEA was performed 
using the Broad Institute platform (http://software.broadinstitute.org) [119]. Samples 
were analyzed with weighted, t-test default settings. The GSE26566 dataset included 
transcriptomes of 104 freshly-frozen tumor tissues and normal biliary epithelial cells 
from 6 non-tumor patients. Differential expressed genes identified if the fold change 
was greater than 2 (up or down) in comparison to control group. Gene sets with a 
false discovery rate (FDR) value < 0.25 after performing 1000 permutations were 
considered to be significantly enriched. 
2.2.18 Statistical analyses 
Data were analyzed using the GraphPad Prism built-in tests. Variables were 
summarized as means ± standard deviation (SD) and depicted graphically as means 
± SD. P values were calculated using the chi-square test or calculated using a two-
sided Student’s t test. Kaplan-Meier survival analysis was used to evaluate overall 
survival rates and disease free survival rate of iCCA patients. P values were 
calculated using the log-rank test. P< 0.05 was considered significant. 
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3 RESULTS 
3.1 Clinical significance of SOX9 
3.1.1 SOX9 expression in chronic liver disease 
Firstly, SOX9 expression was examined in 21 patients with chronic liver disease. 
Immunohistochemistry analyses reveal that in 17 specimens, SOX9 is expressed in 
the nuclei of biliary cells, as located in canals of Hering, reactive ductules and bile 
ducts (Patients 2, 3 and 4, Figure 6), whereas 4 patients show negative SOX9 
immunoreactivity (Patient 1, Figure 6). 
 
Figure 6. Expression of SOX9 in chronic liver disease (Immunohistochemical staining). 
Patient 1 (Pat.1) shows negative SOX9 expression in biliary epithelial cells. Patient (Pat.)  2, 
3 and 4 show strong expression of SOX9 in the nucleus of the canals of Hering, reactive 
ductules and bile duct cells.  
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3.1.2 SOX9 expression in iCCA 
Next, I examined expression of SOX9 and CK19, another cholangiocyte marker, in 
paired liver tissue specimens of 69 iCCA patients (tumor surrounding tissue vs. 
tumor) and 5 eCCA patients by immunohistochemistry. Both, SOX9 and CK19 are 
markers of cholangiocytes, however localize at different cellular compartments. 
SOX9 is expressed in the nuclei of cholangiocytes, while CK19 localizes in cytoplasm 
and membranes. As in chronic liver disease, nuclear immunoreactivity of SOX9 is 
either positive or negative in the cholangiocytes surrounding CCA tumors (Figure 7, 
left panel). In contrast to such more heterogeneous pattern for SOX9, all 
cholangiocytes in the CCA tumor surroundings express CK19 (Figure 7, right 
panel).  
In iCCA tumor tissue, 27% patients highly express SOX9, while 37% patients express 
high levels of CK19. Taking into account intensity of immunoreactivity, four different 
patterns of SOX9 and CK19 expression are defined in iCCA cancer cells, that is 
SOX9highCK19high, SOX9highCK19low, SOX9lowCK19high and SOX9lowCK19low (Figure 
8). Statistically, expression of SOX9 and CK19 in iCCA tumor cells are positively 
associated (P < 0.05, Table 16). From 5 eCCA patients, 4 highly expressed SOX9 
(Figure 9). In all examined tissue specimens, neither SOX9 nor CK19 are detected in 
hepatocytes. 
 
Figure 7. Expressions of SOX9 and CK19 in CCA tumor surrounding tissue 
(Immunohistochemical staining).  
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Figure 8. Expression patterns of SOX9 and CK19 in iCCA tumor tissue 
(Immunohistochemical staining). According to the immunoreaction intensity for SOX9 and 
CK19, four expression patterns of SOX9 and CK19 were defined: SOX9highCK19high, 
SOX9highCK19low, SOX9lowCK19high and SOX9lowCK19low. 
 
Figure 9. Expression of SOX9 in eCCA (Immunohistochemical staining). Patient 1 (Pat.1) 
is negative for SOX9 expression. Patients 2 and 3 show strong SOX9 staining in the nuclei of 
tumor cells. 
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Table 16. Correlation of SOX9 and CK19 expression in iCCA 
CK19 
expression 
SOX9 expression 
No. of  
patients 
P value 
high low 
high 15 11 26 0.033 
low 35 8 43  
 
3.1.3 CCA patients with high SOX9 expression have poor clinical outcome  
Then, I analyzed the relationship between SOX9 or CK19 expression and the clinical 
outcome for the patients, including clinical parameters and patients’ survival time. 
Table 17 shows that SOX9 expression is not associated with the indicated clinical 
parameters, whereas CK19 expression is associated with lymph node involvement 
and the AJCC stage of iCCA (Table 18). Kaplan-Meier analysis and log-rank test 
showed that patients with high SOX9 expression had shorter overall survival (OS) 
and disease free survival (DFS) rates than those with low SOX9 expression (P < 0.01 
and P < 0.05, Figure 10A and B). There is no significant association between CK19 
expression and the OS of the patients (P > 0.05, Figure 10C). Patients with CK19 
high expression show shorter DFS rate in comparison to those with CK19 low 
expression, although this is without a statistical difference (P = 0.0575, Figure 10D). 
Median OS and DFS times of the patients in correlation to SOX9 and CK19 
expression are presented in Tables 19 and 20.  The results reveal that patients with 
high SOX9 expression display shorter median OS time (22 months) than those with 
high CK19 expression (26 months), whereas both presented with the same median 
DFS time (9 months).  
In the presented study, 9 iCCA patients received chemotherapy. SOX9 and CK19 
expression, treatment approaches and clinical outcome of these patients are 
presented in Table 21. Kaplan-Meier analysis and log-rank test show that SOX9 high 
expression patients, who received chemotherapy, had shorter OS rates in 
comparison to those with low SOX9 expression (P=0.0171, Figure 11). There is no 
significant difference in OS rates between CK19 high and low expression patients 
(P=0.6815, Figure 12). Median OS times of the two groups of patients, who received 
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chemotherapy, are 22 and 62 months, respectively (Table 22). These results suggest 
that patients with low SOX9 expression are more sensitive to chemotherapy. 
Table 17. Patient characteristics and tumor parameters in relation to SOX9 
expression in iCCA 
Clinicopathological 
parameters 
SOX9 expression 
No. of the 
patients per 
group 
P value 
low expression 
(n=50) 
high expression 
(n=19) 
Age(year) 64.08±9.24 60.42±10.29 69 0.194 
 
<60 14 8 22 0.261 
 
≥60 36 11 47 
 
Gender 
  
0.296 
 
Male 33 15 48 
 
 
Female 17 4 21 
 
Tumor extension 
 
0.447 
 
T1 19 9 28 
 
 
T2 19 6 25 
 
 
T3 12 2 14 
 
Lymph node involvement 
 
0.219 
 
Yes 12 2 14 
 
 
No 36 16 52 
 
Metastasis 
  
0.079 
 
Yes 7 0 7 
 
 
No 39 18 57 
 
Differentiation grade 
 
 
 
G1 5 1 6 0.634 
 
G2 18 9 27 
 
 
G3 10 3 13 
 
Vascular invasion 
 
0.247 
 
Yes 6 4 10 
 
 
No 41 12 53 
 
Satellite nodules 
 
0.502 
 
Yes 16 4 20 
 
 
No 31 12 43 
 
Cirrhosis 
 
0.318 
 
Yes 11 6 17 
 
 
No 34 10 44 
 
AJCC classification 
 
0.135 
 
I+II 28 13 41 
 
 
II+III 22 4 26 
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Table 18. Patient characteristics and tumor parameters in relation to CK19 
expression in iCCA 
Clinicopathological 
parameters 
CK19 expression 
No. of the 
patients per 
group 
P value 
low expression 
(n=43) 
high expression 
(n=26) 
Age(year) 64.77±9.17 60.27±9.84 69 0.060 
 
<60 11 11 22 0.149 
 
≥60 32 15 47  
Gender   0.260 
 
Male 32 16 48  
 
Female 11 10 21  
Tumor extension 
 
0.394 
 
T1 20 8 28 
 
 
T2 16 9 25 
 
 
T3 7 7 14 
 
Lymph node involvement 
 
0.022 
 
Yes 5 9 14 
 
 
No 36 16 52 
 
Metastasis 
  
0.695 
 
Yes 5 2 7 
 
 
No 34 23 57 
 
Differentiation grade 
 
0.088 
 
G1 6 0 6 
 
 
G2 14 13 27 
 
 
G3 7 6 13 
 
Vascular invasion 
 
0.722 
 
Yes 7 3 10 
 
 
No 34 19 53 
 
Satellite nodules 
 
0.799 
 
Yes 16 4 20 
 
 
No 31 12 43 
 
Cirrhosis 
 
0.929 
 
Yes 11 6 17 
 
 
No 29 15 44 
 
AJCC classification 
 
0.014 
 
I+II 31 10 41 
 
 
II+III 12 14 26 
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Figure 10. Kaplan-Meier survival curves of iCCA patients in relation to SOX9 and CK19 
expression.  
 
Table 19. Median overall survival time of iCCA patients in relation to SOX9 and 
CK19 expression 
Staining and 
expression 
Median survival time (months) 
Overall survival HR (95% CI) P 
SOX9 
Low 52.0 0.2362 (0.085 to 0.656) 0.0056 
High 22.0   
CK19 
Low 38.3 0.6425 (0.291 to 1.417) 0.2728 
High 26.0   
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Table 20. Median disease free survival time of iCCA patients in relation to SOX9 and 
CK19 expression 
Staining and 
expression 
Median survival time (months) 
Disease free survival HR (95% CI) P 
SOX9 
Low 19.3 0.3820(0.163 to 0.893) 0.0263 
High 9   
CK19 
Low 13.9 0.4968(0.241 to 1.023) 0.0575 
High 9   
 
Table 21. SOX9 and CK19 expression and clinical outcome of iCCA patients 
receiving chemotherapy 
SOX9 IHC 
intensity 
CK19 IHC 
intensity 
Death or 
survival 
(1=survival, 0=death) 
Survival 
time  
(months) 
Treatment 
low low 0 23 Gemcitabine plus 
XELOX 
low strong 0 62 Gemcitabine plus 
Cisplatin plus XELOX 
low strong 1 33 Gemcitabine 
low low 1 36 Palliative chemotherapy 
low strong 1 57 Cisplatin plus 
Gemcitabine 
low low 1 51 Palliative chemotherapy 
strong strong 0 14 Erlotinib 
strong strong 0 22 Gemcitabine plus 
Cisplatin 
strong strong 0 41 Palliative chemotherapy 
XELOC: Capecitabine plus Oxaliplatin.  
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Figure 11. Kaplan-Meier survival curve of iCCA patients having received chemotherapy in 
relation to SOX9 expression. 
 
 
Figure 12. Kaplan-Meier survival curve of iCCA patients having received chemotherapy in 
relation to CK19 expression. 
 
Table 22. Median overall survival times of patients having received chemotherapy 
SOX9 expression Median survival time  HR (95% CI) P 
SOX9 
Low 62.0 0.06 (0.006 to 0.605) 0.0171 
High 22.0   
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3.1.4 Integrated analysis of CCA patients gene expression signatures  
To comprehensively elucidate the role of SOX9 in CCA patients, several approaches 
were set up. First, an integrated analysis of gene expression signatures was 
performed with the CCA patient dataset GSE26566, which is publicly available from 
Gene Expression Omnibus (GEO) that included transcriptomes of 104 freshly-frozen 
CCA tumor tissues and “normal” primary biliary epithelial cells isolated from 6 non-
tumor patients. SOX9 is significantly highly expressed in CCA tumor cells as 
compared to normal biliary epithelial cells (Figure 13A and B).  We next categorized 
the 104 CCA patients into SOX9 high (n=66) and SOX9 (n=38) low expression 
groups, based on SOX9 mRNA expression levels being above or below 2 fold of the 
average SOX9 expression in normal NBEC (Figure 13B). 
Subsequently, I performed GSEA to define the CCA related Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways related to SOX9 expression Tables 23 and 
24 (P<0.05 and FDR<0.25). The most significantly enriched pathways in CCA with 
high SOX9 expression are DNA damage repair, more specifically homologous 
recombination and mismatch repair, DNA replication, base excision repair, nucleotide 
excision repair and cell cycle (Figure 13C). SOX9 high expression tumors also 
presented with upregulated epithelial junction genes, such as adherens, tight junction 
and actin cytoskeleton. Additionally, genes associated with Notch, Wnt and mTOR 
signalings are enriched in the SOX9 high expression patients group. Patients with 
low SOX9 expression displayed gene signatures associated with drug metabolism 
pathways, including cytochromes P450 as well as other drug metabolism enzymes 
(Figure 13D). In summary, the results imply that SOX9 expression in CCA is 
associated with DNA damage repair, the formation of tight junction and drug 
metabolism. 
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Figure 13. Integrated analyses of CCA patients gene expression signatures related to SOX9 
expression. A. Expression of SOX9 is higher in CCA tumor tissues as compared to normal 
biliary epithelial cells (NBEC). B. CCA patients were categorized into SOX9 high (Class A) 
and SOX9 low (Class B) expression groups according to the SOX9 mRNA expression in 
CCA. The cutoff value for categorizing the patients was set as 2 fold of average mRNA 
expression of SOX9 in NBECs. C. GSEA showing enrichment of gene signatures associated 
with, among others, homologous recombination, mismatch repair, DNA replication, base 
excision repair and cell cycle in CCA patients with high SOX9 expression. D. Significantly 
enriched gene signatures in SOX9 low CCA patients comprise especially drug metabolism 
enzymes. NES: normalized enrichment score. FDR: false discovery rate. 
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Table 23. GSEA of KEGG pathway ranked by a positive correlation with SOX9 
expression in CCA patients (P<0.05, FDR<0.25) 
Name NES NOM p-val FDR q-val 
CELL_CYCLE  2.21 0.000 0.000 
NOTCH_SIGNALING_PATHWAY  2.18 0.000 0.000 
RIBOSOME  2.15 0.000 0.000 
DNA_REPLICATION  2.12 0.000 0.000 
SPLICEOSOME  2.07 0.000 0.000 
VASOPRESSIN_REGULATED_WATER_REABSORPTION 2.02 0.000 0.001 
HOMOLOGOUS_RECOMBINATION  1.98 0.000 0.001 
ALDOSTERONE_REGULATED_SODIUM_REABSORPTION  1.95 0.000 0.001 
VIBRIO_CHOLERAE_INFECTION  1.94 0.000 0.002 
GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR_BIOSY
NTHESIS  
1.88 0.000 0.002 
PYRIMIDINE_METABOLISM  1.87 0.000 0.002 
BASE_EXCISION_REPAIR  1.85 0.000 0.003 
MISMATCH_REPAIR  1.83 0.014 0.003 
OOCYTE_MEIOSIS  1.77 0.000 0.006 
AMINOACYL_TRNA_BIOSYNTHESIS  1.66 0.000 0.025 
ENDOCYTOSIS  1.61 0.000 0.040 
TIGHT_JUNCTION 1.58 0.000 0.052 
RNA_POLYMERASE  1.57 0.006 0.051 
PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM  1.56 0.000 0.053 
GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLA
CTO_SERIES  
1.55 0.007 0.057 
NUCLEOTIDE_EXCISION_REPAIR 1.55 0.010 0.055 
PURINE_METABOLISM 1.50 0.007 0.088 
ADHERENS_JUNCTION 1.45 0.011 0.123 
PROGESTERONE_MEDIATED_OOCYTE_MATURATION 1.44 0.004 0.127 
CARDIAC_MUSCLE_CONTRACTION 1.44 0.030 0.123 
PATHOGENIC_ESCHERICHIA_COLI_INFECTION 1.44 0.039 0.122 
MTOR_SIGNALING_PATHWAY 1.44 0.033 0.119 
ERBB_SIGNALING_PATHWAY 1.41 0.018 0.143 
REGULATION_OF_ACTIN_CYTOSKELETON 1.40 0.007 0.152 
UBIQUITIN_MEDIATED_PROTEOLYSIS 1.38 0.011 0.158 
FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 1.38 0.000 0.154 
RENAL_CELL_CARCINOMA 1.35 0.021 0.187 
WNT_SIGNALING_PATHWAY 1.30 0.049 0.240 
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Table 24. GSEA of KEGG pathways ranked by negative correlation with SOX9 
expression in CCA patients (P<0.05, FDR<0.25) 
Name NES NOM p-val FDR q-val 
PPAR_SIGNALING_PATHWAY  1.92 0.003 0.041 
LINOLEIC_ACID_METABOLISM  1.86 0.003 0.046 
RETINOL_METABOLISM  1.74 0.014 0.120 
FATTY_ACID_METABOLISM  1.73 0.001 0.108 
COMPLEMENT_AND_COAGULATION_CASCADES  1.68 0.007 0.141 
ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM  1.67 0.021 0.138 
TRYPTOPHAN_METABOLISM  1.67 0.006 0.125 
PRIMARY_BILE_ACID_BIOSYNTHESIS  1.66 0.003 0.120 
STEROID_HORMONE_BIOSYNTHESIS  1.64 0.038 0.124 
PEROXISOME  1.64 0.019 0.115 
DRUG_METABOLISM_CYTOCHROME_P450  1.63 0.033 0.106 
PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS  1.62 0.027 0.109 
GLYCINE_SERINE_AND_THREONINE_METABOLISM  1.62 0.008 0.102 
VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION  1.60 0.011 0.116 
METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450  1.56 0.046 0.150 
PROPANOATE_METABOLISM  1.56 0.012 0.144 
ASCORBATE_AND_ALDARATE_METABOLISM  1.55 0.014 0.146 
DRUG_METABOLISM_OTHER_ENZYMES  1.51 0.047 0.187 
PRION_DISEASES  1.50 0.031 0.189 
STARCH_AND_SUCROSE_METABOLISM  1.50 0.033 0.179 
BETA_ALANINE_METABOLISM 1.49 0.032 0.185 
BUTANOATE_METABOLISM 1.49 0.047 0.178 
TYROSINE_METABOLISM 1.46 0.038 0.213 
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3.2 Investigating SOX9 function in CCA tumorigenesis and chemotherapy in vitro 
3.2.1 SOX9 is highly expressed in CCA cell lines 
SOX9 and CK19 protein expression were examined in CCA cell lines CC-SW-1, 
HuCCT-1, HCCC-9810, EGI-1 and TFK-1, as well as in the normal biliary epithelial 
cell line MMNK-1 using immunoblotting. Both SOX9 and CK19 is highly expressed in 
CCA cells in comparison to MMNK-1 (Figure 14). 
 
Figure 14. Expression of SOX9 and CK19 in CCA cell lines and normal biliary epithelia cell 
line MMNK-1 (immunoblot, Tubulin was used as loading control).  
3.2.2 Comparative microarray analysis of parental and SOX9 depleted CC-SW-1 
cells 
In a second approach to position SOX9 in the cellular fate of CCA tumors, small 
interfering RNAs were used to knock down SOX9 expression in the above CC-SW-1 
cells. SOX9 mRNA depletion was confirmed by immunoblot showing a significantly 
reduced signal after treating the cells with SOX9 siRNA for 48 hours (Figure 15). In 
this stage, I purified the mRNA from knock down and control cells and a microarray 
analysis was performed to evaluate the respective gene expression signatures. 
Figure 16A shows 146 upregulated and 222 downregulated genes (Fold change > 2) 
upon SOX9 depletion. GSEA revealed that upregulated genes (that is suppressed 
from SOX9 in parental cells) were enriched in KEGG pathways (P < 0.05 and FDR < 
0.25) relating to p53, MAPK signaling, complement and coagulation cascades 
(Figure 16B). Downregulated genes (that is under the control of SOX9 in parental 
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cells) enriched in KEGG pathway are related to cytochrome P450 related metabolism 
of xenobiotics and drugs, mTOR signaling pathway (P<0.05 and FDR<0.25). In detail, 
genes dedicated for drug metabolism comprise UGT1A6, UGT1A9, ALDH1A3, 
GSTA2, GSTA4, AKR1C3 and MAOB, and related to adenosine triphosphate (ATP)–
binding cassette (ABC) transporters include ABCB1 and ABCC4 (Figure 17A). 
Upregulated genes that integrate into the p53 pathway are FAS, SFN and PMAIP1 
(Figure 17A). In addition, SOX9 inhibition decreases expression of genes related to 
the actin cytoskeleton, including PIK3R, PDGFD, FGFR2 and FGFR4. Moreover, 
SOX9 silencing dysregulated genes related to cell adhesion, including upregulation 
of CLDN1, CDH4, NEGR1, JUN, ITGA2, LAMB3 and LAMC2, whereas 
downregulation of CDH1, HLA-DMA, NLGN1, CADM1 and EGR1 (Figure 17B). 
Taken together, microarray analysis implied that SOX9 in CCA cells has impacts on 
cellular fate related to drug metabolism, survival and cell adhesion.  
 
 
Figure 15. SOX9 expression in CCA cells with or without SOX9 siRNA treatment for 48 
hours (immunoblot, Tubulin was used as loading control). 
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Figure 16. Comparative microarray analysis of CC-SW-1 cells with SOX9 knockdown as 
compared to control cells. A. Pie chart shows gene expression changes of more than 2 fold. 
B. Bar plots for enriched KEGG pathways of the top 146 upregulated and 222 downregulated 
genes (P<0.05 and FDR<0.25). 
 
 
 
Figure 17. Heatmap illustration of the gene expression analyses in CC-SW-1 CCA cells with 
or without SOX9 siRNA treatment. A, B. Heatmap graphs showing Sox9 dependent genes 
relating to pathways as indicated. ABC, adenosine triphosphate (ATP)–binds cassette. 
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3.2.3 Depleting SOX9 suppresses CCA cell survival 
Then, I investigated the function of SOX9 on CCA cell survival. The MTT assay 
shows that knockdown of SOX9 expression inhibits cell viability of CCA cells (Figure 
18). Then, cell cycle analyses reveal that SOX9 knockdown significantly decreases 
the proportion of cells in G1 phase, whereas cell numbers in G2/M phase are 
increased in both CC-SW-1 and EGI-1 cells (Figure 19). Immunoblots further show 
that depleting SOX9 reduces the expression of cyclin-dependent kinase inhibitors 
p27 and p16, whereas p21 expression is induced in CC-SW-1 cells (Figure 20). EGI-
1 cells, in contrast to CC-SW-1 cells, show the opposite result regarding p21 (Figure 
20). Importantly, SOX9 inhibition induced cell apoptosis in both CC-SW-1 and EGI-1 
cells (Figure 21). Disruption of SOX9 had no effect on the expression of anti-
apoptotic proteins Bcl-xL and Bcl-2, cell cycle regulatory proteins Cyclin D1 and p53 
in the two CCA cell lines, indicating that the observed pro-proliferative SOX9 effect 
does not involve these components of the cell cycle/apoptosis machinery (Figure 22). 
 
Figure 18. Cell viability measured by MTT assay in CCA cells with or without SOX9 
knockdown. **: P<0.01, **** : <0.0001. 
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Figure 19. SOX9 and cell cycle progression in CC-SW-1 and EGI-1 cells. A. Comparative 
cell cycle analyses of CC-SW-1 and EGI-1 CCC cell lines treated with control or SOX9 
targeting siRNA. B. Respective quantification of CC-SW-1 and EGI-1 cells in the different cell 
cycle phases upon control or SOX9 siRNA treatment. The results are presented as mean ± 
SD. *: P<0.05. **: P<0.01. 
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Figure 20. SOX9 and expression of cyclin-dependent kinase inhibitors in CC-SW-1 and EGI-
1 cells (immunoblot assay, Tubulin was used as loading control). 
 
 
Figure 21. SOX9 and expression of cleaved caspase 3 in CC-SW-1 and EGI-1 cells 
(immunoblot assay, Tubulin was used as loading control). 
 
 
Figure 22. SOX9 and expression of anti-apoptotic proteins Bcl-xL and Bcl-2, cell cycle 
regulatory proteins Cyclin D1 and p53 in CC-SW-1 and EGI-1 cells (immunoblot assay, 
GAPDH was used as loading control). 
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3.2.4 SOX9 is required for cell migration  
Next, I assessed the role of SOX9 on CCA cell migration. Transwell assays show that 
SOX9 knockdown significantly inhibits cell migration in CC-SW-1 and HuCCT-1 cells 
(Figure 23). To further investigate whether the role of SOX9 on cell migration 
involves EMT, I examined epithelial and mesenchymal cell marker expression in CCA 
cells as a function of SOX9 presence or depletion. SOX9 knockdown at least does 
not change expression of cell adhesion marker E-Cadherin and mesenchymal cell 
markers N-Cadherin and Vimentin (Figure 24).  Moreover, immunoblot assays and 
immunofluorescence staining show that SOX9 reduction has no effect on β-Catenin 
nuclear translocation in the tested CCA cells (Figures 25 and 26).  These results 
suggest that the impact of SOX9 on CCA migration is not EMT-dependent.  
 
Figure 23. SOX9 and CCA cell migration, as measured by transwell assays. A. Transwell 
assays were performed in CC-SW-1 and HuCCT-1 cells transfected with control or SOX9 
siRNA as indicated. B. Quantification of cell migration (red cell number) in CC-SW-1 and 
HuCCT-1 treated with control or SOX9 siRNAs. Results are presented as mean ± SD. *: 
P<0.05. ***: P<0.001. 
 
 
RESULTS 
57 
 
Figure 24. SOX9 and expression of epithelial cell marker E-Cadherin or mesenchymal cell 
markers N-Cadherin and Vimentin (immunoblot assay).  
 
Figure 25.  SOX9 and subcellular localization of β-Catenin in CC-SW-1 and HuCCT-1 cells 
(immunoblot assay upon nuclear/cytoplasmic fractionation). 
 
Figure 26. Expression of E-Cadherin and β-Catenin in HuCCT-1 cells treated with control or 
SOX9 siRNA (immunofluorescence). 
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3.2.5 SOX9 is required for CCA cell stemness 
In HCC, SOX9 is recognized as a CSC marker, participating in CSC self-renewal, 
transdifferentiation and tumorigenicity. To investigate whether SOX9 is also related to 
cancer stemness of CCA cells, I performed tumor sphere formation assays, a widely 
used method to evaluate self-renewal and differentiation of CSC in vitro [120]. In CC-
SW-1 cells, SOX9 knockdown significantly inhibits tumor sphere formation capacity 
(Figure 27). Moreover, silencing SOX9 expression reduces expression of EpCAM at 
mRNA and protein levels (Figure 28). EpCAM has been known as a marker for 
maintaining CSC-features in HCC.  
CSC-derived tumors display an impressive capacity to resist to chemotherapy, which 
is at least partially due to high level adenosine triphosphate (ATP)–binding cassette 
(ABC) transporter expression [121]. In CCA cells, immunoblot assays show that 
SOX9 knockdown downregulates expression of multidrug resistance protein 4 
(MRP4), also known as ATP-binding cassette sub-family C member 4 (ABCC4), 
which belongs to the ABCC family of multidrug resistant genes (Figure 29A). In 
consistent with microarray data (Figure 17A), where CC-SW-1 cells with SOX9 
knockdown have decreased ATP-binding cassette (ABC) transporters ABCB1 and 
ABCC4, real-time PCR displays that SOX9 depletion reduces expression of multidrug 
resistance genes ABCB1, as well as other genes including ABCG2 and ABCC6 
(Figure 29B). The results implied that SOX9 may be critical to maintain the stem cell 
features of CCA.  
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Figure 27. SOX9 and CC-SW-1 tumor sphere formation. A. Representative picture of CC-
SW-1 cells tumor sphere formation upon treatment with SOX9 or control siRNA. B. 
Quantification of tumor sphere formation (Tumor spheres above 100 µm are considered as 
positive) upon treatment with SOX9 or control siRNA. *: P<0.05. 
 
Figure 28. SOX9 and CCA transdifferentiation. A. Real-Time PCR showing that SOX9 
knockdown inhibits EpCAM expression at RNA level.  B. Immunoblot showing that SOX9 
knockdown decreases EpCAM expression at the protein level. GAPDH was used as loading 
control. 
 
Figure 29. SOX9 and multidrug resistance gene expression. A. Immunoblot showing that 
SOX9 knockdown decreases expression of multidrug resistance-associated protein 4 
(MRP4). GAPDH was used as loading control. B. Real-Time PCR showing that SOX9 
knockdown downregulates expression of multidrug resistance genes ABCB1, ABCG2 and 
ABCC6. 
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3.2.6 SOX9 inhibition sensitizes CCA cells to gemcitabine 
To investigate SOX9 in CCA chemotherapy, I treated CCA cells with gemcitabine, an 
analog of deoxycytidine widely used for treatment of multiple cancers, including CCA. 
Interestingly, immunoblots revealed that SOX9 expression is increased upon 
gemcitabine treatment, both in CC-SW-1 and EGI-1 cells (Figure 30). Next, I treated 
CC-SW-1 and EGI-1 cells with gemcitabine for 24 hours upon control or SOX9 siRNA 
transfection and comparatively measured survival using MTT assays. Depletion of 
SOX9 shows significantly reduced IC50 values (Figure 31), which is in CC-SW-1 
cells, gemcitabine/SOX9 siRNA = 2.0 ± 0.23nM vs control = 7.1 ± 0.15nM, and in 
EGI-1, gemcitabine/SOX9 siRNA = 46.3 ± 21.9nM vs control = 380.3 ± 249.1nM. 
These results demonstrate that upregulated SOX9 expression protects CCA cells to 
gemcitabine induced cell apoptosis. In addition, immunoblots reveal that combination 
treatment downregulated multidrug resistance-associated protein 4 expression in CC-
SW-1 cells, and inhibited the activation of Checkpoint kinase 1 (Chk1) both in CC-
SW-1 and EGI-1 cells (Figure 32). Finally, immunoblots and Caspase 3 assays 
confirm that gemcitabine induces significant cell death in CC-SW-1 and EGI-1 cells 
upon SOX9 knockdown as compared to control cells (Figure 33).  
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Figure 30. SOX9 expression in CC-SW-1 and EGI-1 cells treated with indicated 
concentration of gemcitabine (immunoblot, Tubulin was used as loading control). 
 
 
 
 
Figure 31. IC50 evaluation of gemcitabine using MTT method in CC-SW-1 and EGI-1 cells 
treated with or without SOX9 siRNA for 24 hours. 
 
 
RESULTS 
62 
 
Figure 32. SOX9 regulates expression of MRP4 and phosphorylation Chk1 in CCA cells. A. 
Immunoblot of MRP4 expression in CC-SW-1 cells with the indicated treatments. B. 
Immunoblot showing expression respective phosphorylation of Checkpoint kinase 1 (Chk1) in 
CC-SW-1 and EGI-1 cells. GAPDH was used as loading control. 
 
Figure 33. SOX9 and gemcitabine mediated CCA cell apoptosis. A. Immunoblot showing 
Cleaved caspase 3 and 8 expression in CC-SW-1 and EGI-1 cells with the indicated 
treatments. Tubulin was used as loading control.  B. Caspase 3 assay as performed in CC-
SW-1 and EGI-1 cells with the indicated treatments.  
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3.2.7 SOX9 is downstream of EGFR/ERK1/2 signaling 
EGF/EGFR signaling was described as key to govern migration and invasion of CCA 
cells via an EMT process [81].  I have shown above that SOX9 facilitates cell 
migration of CCA cells. To assess a potential relationship between SOX9 and 
EGF/EGFR signaling, I treated CCA cells with EGF (10ng/ml) for 24 hours, and 
observed that the cells became scattered with appearance of membrane protrusions 
(Figure 34A). Immunoblots revealed that EGF treatment decreases expression of 
epithelial marker E-Cadherin, whereas expression of the mesenchymal marker 
Vimentin increases (Figure 34B), supporting a role of EGF/EGFR signaling to induce 
EMT in CCA cells. Of note, SOX9 expression is also upregulated upon EGF 
treatment and this is inhibited, when the cells are treated with EGFR inhibitor Erlotinib 
or ERK1/2 inhibitor U0126 (Figure 35). These results indicate that EGFR/ERK1/2 
signaling upregulates SOX9 expression in CCA cells. Then, I investigated if SOX9 
participates in EGF/EGFR-mediated CCA cell migration. Therefore, I performed 
transwell assays with CCA cells treated with EGF and control or in SOX9 siRNA. 
SOX9 knockdown significantly inhibits EGF-induced CCA cell migration (Figure 
36A). However, immunoblots show that SOX9 depletion has no effect on EMT 
marker expression, regardless of EGF treated or not (Figure 36B). These results 
suggest that SOX9 is a downstream effector of EGFR/ERK1/2 signaling pathway and 
is directly involved in CCA cell motility, whereas EMT occurs independent and in 
parallel to Sox9 expression induction. 
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Figure 34. EGF and CCA cells. A. Representative phase-contrast images of CC-SW-1 
treated with 10ng/ml EGF for 24 hours and controls. B. Immunoblot of EGF impact on 
expression of SOX9, E-Cadherin and Vimentin. Tubulin was used as loading control. 
 
 
Figure 35. EGFR/ERK1/2 signaling and SOX9 expression. A. Immunoblot for SOX9 in CC-
SW-1 and HuCCT-1 cells treated with EGF for 24h. Erlotinib is an EGFR inhibitor. B. ERK1/2 
pathway and SOX9 expression in CC-SW-1 and HuCCT-1 cells. U0126 is an ERK1/2 
inhibitor. Tubulin and GAPDH were used as loading control. 
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Figure 36. SOX9 and EGFR/ERK1/2 signaling induced cell migration. A. Representative 
images of transwell assays in CC-SW-1 cells treated with EGF (10ng/ml for 24hours) and 
control or SOX9 siRNA. B. Immunoblot showing that knockdown of SOX9 does not affect 
expression of E-Cadherin and Vimentin with and without EGF treatment. Tubulin was used 
as loading control. 
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4 DISCUSSION 
The major findings of the study are: (1) SOX9 is a more sensitive marker for the 
prognosis of iCCA in comparison to CK19; (2) SOX9 determines the CCA cell 
response to chemotherapy; (3) SOX9 is critical for CCA cell survival, migration, self-
renewal and differentiation.  
4.1 SOX9 is a prognostic marker for iCCA 
CK19 and SOX9 are classical markers for cholangiocytes. CK19 contributes to the 
differentiation of iCCA from metastatic adenocarcinoma and is associated with the 
histological differentiation of iCCA. Shimonishi et al. demonstrated that moderate and 
extensive expression of CK19 was associated with well-differentiated iCCA, whereas 
decreased expression of the protein is associated with the poorly differentiated 
cancer [122]. However, Demarez et al. reported that CK19 expression in iCCA 
patients does not correlate with the iCCA histological differentiation grade [123]. In 
the iCCA patients of the present study, CK19 expression is associated with the tumor 
differentiation grade. Moreover, CK19 expression correlates with AJCC classification 
of iCCA.  
In the current cohort of iCCA patients, SOX9 expression is correlated with CK19 
expression, it does not associate with any analyzed clinical parameters, including 
cirrhosis, vascular invasion and AJCC classification.  Of note, survival analysis 
revealed that patients with high SOX9 expression present with the shortest OS and 
DFS times in comparison to patients with high CK19 expression or low SOX9 
expression. These results indicate that currently measured clinical parameters in 
clinical practice are not capable of evaluating any potential effects of SOX9 on CCA 
progression. Despite this fact, SOX9 expression is more sensitive to predict the 
clinical outcome of iCCA patients in comparison to CK19. 
4.2 SOX9 determines the response of CCA cells to chemotherapy 
To clarify the potential role of SOX9 in CCA, I investigated SOX9 expression and the 
clinical outcome of 9 CCA patients who received chemotherapy. Survival analysis 
showed that patients with SOX9 low expression had significantly longer OS time than 
those with high SOX9 expression after chemotherapy, indicating that SOX9 
expression in cancer cells may determine the survival time of CCA patients who 
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received chemotherapy and therewith suggesting a critical role of SOX9 in 
chemoresistance of CCA cells.  
Besides the clinical findings, several additional lines of evidence supported the link 
between SOX9 expression and multidrug resistance. The integrative analysis of gene 
expression signatures in 104 CCA patients showed that SOX9 expression is 
positively correlated with DNA repair pathways including homologous recombination 
and mismatch repair, DNA replication, base excision repair, as well as nucleotide 
excision repair. It has been demonstrated that the ability of cancer cells to repair 
therapeutically induced DNA damage facilitates cancer cell survival and impacts 
therapeutic efficacy [124]. Hence, targeting DNA repair pathways has been proposed 
as a strategy for the development of anti-cancer agents to consequently increase 
sensitivity to chemotherapeutics. To date, inhibitors of DNA damage repair pathways 
have entered several clinical trials, either as a monotherapy or in combination with 
chemotherapeutics [124, 125]. In addition, SOX9 expression is positively correlated 
with Wnt and Notch signaling pathways, both demonstrated to account for 
chemoresistance of cancer cells to gemcitabine through inactivating the apoptosis 
pathway, increasing the expression of drug efflux pumps or activating CSCs 
formation [114].  Thus, my data suggests that SOX9 integrates in DNA repair 
pathways, Wnt and Notch signaling in the context of chemoresistance for CCA 
patients.  
Microarray analyses from cultured CCA cells reveal that the expression of genes 
related to multidrug resistance genes, including ABCB1 and ABCC4, are positively 
regulated by SOX9. Treatment of CCA cells with gemcitabine, a widely used 
chemotherapeutic agent in cancer, induces SOX9 expression, which further confirms 
the relationship between SOX9 expression and chemoresistance. IC50 decreases 
significantly and apoptosis rate is higher in gemcitabine treated CCA cells upon 
SOX9 knockdown. Moreover, expression of proteins critical for multidrug resistance, 
DNA stability and DNA repair, very interestingly MRP4 and pChk1, are blunted with 
SOX9 expression depletion. Chk1 functions as regulator of the G2/M checkpoint and 
is crucial for replication fork stability, replication origin firing and homologous 
recombination, particularly in cells which are facing genotoxic stress [126]. In 
gemcitabine-treated cancer cells, Chk1 inhibition rapidly results in cell death due to 
destabilization of the DNA replication apparatus [127]. Therefore, targeting Chk1 has 
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become a strategy for improving chemotherapy and several inhibitors of Chk1 have 
entered clinical trials either as stand-alone agents or in combination with radiotherapy 
or chemotherapy [128]. The present study now suggests SOX9 as a critical 
component for Chk1 phosphorylation, although the underlying mechanism requires 
further investigation. Taken together, my data demonstrates that SOX9 inhibition 
sensitizes CCA cells to chemotherapeutics by inducing cell apoptosis, suppressing 
the efflux of chemotherapeutic drugs and reducing tumor cell DNA repair ability upon 
chemotherapeutic agents induced DNA damage. Therefore, SOX9 expression levels 
have potential to predict chemoresistence and efficacy of chemotherapy in CCA 
patients. 
4.3 SOX9 as oncogene in CCA 
In 2000, Hanahan D and Weinberg RA proposed six hallmarks of cancer as follows: 
(1) sustaining proliferative signaling, (2) evading growth suppressors, (3) resisting cell 
death, (4) enabling replicative immortality, (5) inducing angiogenesis, and (6) 
activating invasion and metastasis [129]. In 2011, four additional cancer hallmarks  
were added to the list, which are (7) genome instability and mutation, (8) tumor-
promoting inflammation, (9) reprogramming energy metabolism and (10) evading 
immune destruction [130]. These cancer cells hallmarks are acquired during the 
multi-step process of cancer development. In the present study, in the context of the 
above features, I investigated the role of SOX9 in survival, migration and cancer stem 
cell features in CCA cells. 
4.3.1 Survival 
Previous studies assessed the role of SOX9 in cancer cell survival. SOX9 knockdown 
in lung adenocarcinoma CL1-5 cells decreased the cell fraction in G1 phase and 
increased that in G2/M phase, which consequently resulted in cell proliferation 
inhibition [24]. The altered cell cycle distribution induced by SOX9 depletion was 
attributed to increased p21 and decreased CDK4 expression. In contrast to these 
data, SOX9 overexpression in melanoma cells inhibited cell proliferation due to 
increased p21 expression and cell cycle arrest in G1 phase [25]. Consistent with the 
former report, my results show that SOX9 knockdown results in a similar cell cycle 
distribution in both CC-SW-1 and EGI-1 cells, although p21 expression is increased 
in CC-SW-1 and decreased in EGI-1 as compared to the parental cells. Furthermore, 
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cell apoptosis was significantly induced by SOX9 knockdown in both CCA cell lines. 
As an explanation for these contradicting data, we and others previously described 
p21 as protein with context dependent functions that sometimes present with 
opposite outcome [131, 132]. For instance, in mice with severe liver injury p21 
deletion led to continuous hepatocyte proliferation but also facilitated rapid tumor 
development, whereas in p21-deficient mice with moderate injury liver regeneration 
and hepatocarcinogenesis were impaired [131]. As a negative regulator of cell cycle, 
p21 is involved in cell apoptosis and cell cycle distribution. Thereby, high p21 
expression in the cytoplasm facilitates apoptosis, while its accumulation in nucleus is 
related to cell cycle arrest [133]. Taken together, the opposing results revealed the 
function of SOX9 on p21 expression is cancer cell dependent.  In addition, whether 
SOX9 inhibition-induced cell cycle alteration and apoptosis is p21 dependent needs 
further investigation.  
SOX9 inhibition-induced cell apoptosis might be associated with p53-related 
signaling. The notion was supported by a microarray analysis showing upregulation 
of p53 signaling pathway-related genes in CC-SW-1 cells with SOX9 knockdown, e.g. 
FAS, SFN and PMAIP1, all of which are essential mediators of cell apoptosis [134-
136]. p53, as a tumor suppressor, can be activated by DNA damage, hypoxia and 
aberrant oncogene expression [137, 138].  Activated p53 functions to integrate 
multiple stress signals into a series of diverse anti-proliferative responses by 
activating and decreasing number of genes involved in cell death, senescence, or 
cell cycle arrest [138]. In the current study, although SOX9 knockdown in CCA cells 
has no effects on the p53 expression, SOX9 inhibition significantly increases cleaved 
caspase 3 and 8 expression and subsequently induces cell apoptosis. Hence, 
whether SOX9 inhibition induced cell apoptosis is p53 pathway dependent needs 
further investigation. Nevertheless, these facts provide evidence that dysregulation of 
SOX9 expression is associated with cell cycle progression and consequently affects 
the proliferation and survival of CCA cells.  
4.3.2 Migration 
EMT is a biologic process that allows a polarized epithelial cell to acquire a 
mesenchymal fate [139]. Cancer cells through EMT process acquire cell-biological 
traits associated with high-grade malignancy, including resistance to apoptosis, 
motility and invasiveness [140]. In the present study, I present in vitro evidence that 
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SOX9 is necessary for efficient cancer cell migration in CCA tumor cells. In short, 
starting with an examination of the “usual suspects” of EMT, SOX9 knockdown 
significantly inhibits cell migration while has no effects on the expression of epithelia 
cell marker and mesenchymal marker in CCA cells. On one hand, migration of these 
cells is significantly blunted upon SOX9 knockdown. Looking at microarray data, 
SOX9 expression is associated with genes related to regulation of actin cytoskeleton, 
cell-cell contacts and focal adhesion. Interestingly in this context, I further found out 
that SOX9 expression is regulated by the EGF/EGFR/ERK1/2 pathway and required 
for cell migration induced by EGF stimulation of CCA cells. These results are 
consistent with Ling’s report describing the contribution of the EGFR/ERK1/2/SOX9 
pathway to malignant transformation of stressed urothelial cells, as well as migration 
and invasion of urothelial cancer cells [141]. On the other hand, in CCA, SOX9 
inhibition is not involved in the route of EGF induced expression of EMT markers. In 
summary, my data reveal that in vitro, SOX9 expression is regulated by the 
EGF/EGFR/1/2 pathway and is an essential component of EGF-induced CCA cell 
migration.  
4.3.3 Cancer stem cell features  
CSCs are highly tumorigenic, metastatic, chemo- and radiation therapy resistant, and 
able to divide symmetrically and asymmetrically to orchestrate tumor mass and 
account for tumor relapse [142]. As a marker of cholangiocytes, SOX9 is expressed 
in HPCs but not in hepatocytes. In HCC, cancer cells that express SOX9 are thought 
as CSC-derived, since a role of SOX9 in maintaining CSCs properties in HCC is 
known. For example, SOX9 is required for acquiring stemness and chemoresistance 
of HCC cells [46]. Further, SOX9 is essential for symmetric cell division and self-
renewal of CSCs in HCC [47]. So far, it is unclear whether SOX9 expression in CCA 
is related with the CSC fate. In the present study, I show that SOX9 depletion inhibits 
tumor sphere formation of CCA cells, suggesting its participation in self-renewal. Of 
note, SOX9 silencing decreases EpCAM expression. In normal liver, EpCAM is a 
differentiation marker of cholangiocytes and hepatocytes lack its expression [143]. In 
HCC, EpCAM expression is essential for maintaining CSC features [144]. In CCA, 
EpCAM was reported as a poor prognostic marker and subsequently dedicated as a 
marker for CSCs [145]. This link between SOX9 and EpCAM provides the first 
evidence that SOX9 may play a role in CCA related CSC generation. In addition, 
CSCs are more resistant to chemotherapeutic agents than differentiated tumor cells, 
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due to increased expression of ATP-binding cassette transporters [121]. In vitro, 
SOX9 inhibition disrupted the expression of several multidrug resistance genes and 
consequently sensitized CCA cells to gemcitabine. Taken together, these facts 
illustrated that SOX9 might be an essential regulator for maintaining CSC-features of 
CCA. 
4.4 Regulation of SOX9 expression  
Gene expression profiling of publicly available CCA patient data sets revealed that 
SOX9 expression is associated with the Notch pathway. In liver, Notch is critical for 
activation, proliferation and differentiation of hepatoblasts/HPCs [96, 98]. SOX9 is a 
well described target gene of the Notch pathway. Aberrant activity of Notch related 
signaling is involved in tumorigenesis of CCA [65]. These facts implied SOX9 might 
be involved in Notch pathway during the carcinogenesis of CCA. As discussed 
above, I revealed that EGF/EGFR/ERK1/2 participate in the regulation of SOX9 
expression in CCA cells. A relationship between EGFR/ERK1/2 and Notch pathways 
exists in the context of cholangiocyte differentiation [146]. However, the network of 
EGFR/ERK1/2, Notch and SOX9 in CCA has not been delineated yet. Maybe we can 
learn something from HCC. There, SOX9 regulates the Notch pathway via inhibition 
of Numb, a Notch signaling antagonist, which results in maintenance of CSCs-
features [47]. Also this aspect contains substance for future studies. 
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5 SUMMARY 
SOX9 is a critical transcription factor for liver embryogenesis, homeostasis and HCC 
development. However, the oncogenic role of SOX9 has not been investigated in 
CCA. As CCA is a devastating malignancy with limited treatment options, elucidation 
of its underlying mechanisms and identification of new molecular markers of 
tumorigenesis and progression of CCA is necessary for improving diagnosis and 
prognosis of this cancer type. This study aims at investigating the effects and 
underlying mechanisms of SOX9 in tumorigenesis and chemotherapy of CCA. 
 
In this thesis, I examined SOX9 expression in CCA patients, including intrahepatic 
CCA (iCCA) and extrahepatic CCA (eCCA), by immunohistochemistry. Association of 
SOX9 expression and clinical outcome was evaluated. A SOX9 gene signature and 
its biological functions were investigated in CCA cell lines. My results reveal that 
SOX9 expression is significantly associated with overall survival of iCCA patients, 
with high SOX9 expression presenting with a shorter survival time, as compared to 
patients with low SOX9. Impressively, in the investigated patient cohort, CCA patients 
with low SOX9 levels have 62 months of median survival time following 
chemotherapy, whereas median survival time is only 22 months for patients with high 
SOX9 expression. In vitro, gemcitabine treatment induces SOX9 expression in CCA 
cells. When SOX9 is knocked down by small interfering RNA (siRNA), gemcitabine-
induced cell death is markedly increased. Molecularly, SOX9 silencing inhibits 
gemcitabine-induced phosphorylation of checkpoint kinase 1 (CHEK1), a key cell 
cycle check point regulator that coordinates the DNA damage response and 
expression of multidrug resistance genes. Microarray analyses show that SOX9 
knockdown in CCA cells alters the gene signature with respect to adenosine 
triphosphate–binding cassette (ABC) transporters, drug metabolism enzymes and 
p53 signaling. Moreover, I demonstrate that SOX9 expression is required for survival, 
migration and stemness of CCA cells. Finally, I found out that EGFR/ERK signaling is 
important in regulating SOX9 expression in CCA cells. 
 
In conclusion, my thesis has revealed that (1) SOX9 is critical for CCA cell survival, 
migration and CSCs-features, (2) governs the response of CCA cells to 
chemotherapy through regulating activation of CHEK1and multidrug resistance 
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genes. (3) My data also provides a strong rational for a clinical study to confirm SOX9 
as a biomarker to predict which CCA patients are eligible for efficient chemotherapy. 
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